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In silence, in steadiness, in severe abstraction,  
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that this day he has seen something truly 
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Introduction 
 
Section 1  Lynch syndrome 
 
1.1  Lynch syndrome: introduction 
Fundamentally cancer is a genetic disorder, meaning that a cell needs 
genetic changes to confer a selective growth advantage before becoming a 
cancer cell. Such genetic alterations mostly occur somatically, however, 
mutations through the germline might result in a high cancer risk and 
predispose to early-onset cancer (1). Colorectal cancer (CRC) is one of the 
most prevalent cancer types in the Western world, with Lynch syndrome, 
also known as hereditary nonpolyposis colorectal cancer (HNPCC), as the 
most common type of hereditary CRC. 
Lynch syndrome was first described in 1913 by Alfred Warthin, a pathologist 
who described the family of his seamstress (2). That it was an inherited 
disease, with an autosomal dominant pattern of inheritance, was 
rediscovered in the mid-1960s by Henry Lynch (3). He also noticed that in 
addition to colon cancer, extracolonic malignancies occurred. As Lynch did 
recognise the syndrome, it was and is still called Lynch syndrome. In 1991, 
the international collaborative group on hereditary nonpolyposis colorectal 
cancer (ICG-HNPCC) formulated the Amsterdam criteria to clinically define 
the disease and to make research on this subject better comparable (4). 
The families meeting some but not all of these Amsterdam (II) criteria often 
are classified as “suspected for Lynch syndrome” or, more briefly, “Lynch 
syndrome suspected”. In particular for genetic screening of these 
suspected patients additional selection criteria have been developed as this 
group of patients includes many patients that can “genetically” be classified 
as Lynch syndrome (e.g. have a germline pathogenic mutation in one of the 
MMR genes). Berends et al. (5) reviewed the attempts of various groups to 
define new criteria to select patients for mutation analysis.  
Estimations of the proportion of clinical cases with Lynch syndrome of the 
total of colorectal cancers, based on the Amsterdam criteria, varied from 
less than 1% in Finland to 13% in the United Kingdom (6;7). 
 
1.2 Genetic predispositions causing Lynch syndrome 
As mentioned, a cell needs multiple genetic alterations before it becomes a 
cancer cell. It has been proposed that cells need to acquire a “mutator 
phenotype” at an early stage of tumourigenesis to enable the accumulation 
of multiple genetic aberrations (8). This hypothesis was proven for Lynch 
syndrome in the early nineties. It was the finding of numerous somatic 
mutations in the tumours of patients with Lynch syndrome in combination 
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with linkage analysis that resulted in the identification of inherited 
heterozygous defects in two genes encoding proteins that function in the 
maintenance of genomic stability, the DNA mismatch repair (MMR) genes 
MLH1 and MSH2. Later other MMR genes, PMS2 and MSH6, were 
identified as less frequently involved genes for this cancer syndrome (as 
reviewed in (9;10)). 
Recently, several population-based studies concluded that genetically 
proven Lynch syndrome, c.q. families having mutations in MLH1 and 
MSH2, accounts for 0.3% to 2.7% of all colorectal cancer cases (11;12). 
 
1.3 Mismatch repair system 
The MMR system comprises an evolutionary conserved set of proteins that 
recognises and removes replication errors that are not immediately 
corrected by the proofreading activities of replicative DNA polymerases, 
thereby providing a secondary system of proofreading. This system 
corrects not only single base-pair mismatches but also small 
insertion/deletion loops (IDLs) that result from slippage of the replicative 
polymerases while replicating microsatellites consisting of mono- or di-
nucleotide repeats. The ability of many species to repair mismatches in 
double-stranded DNA has been well documented. The first critical step in 
this process is the recognition of the mismatched DNA. In the best 
documented mismatch repair system, the one in Escherichia coli, the MutS 
protein accomplishes this. A homodimer of the MutS protein binds to the 
site of a mismatch in double-stranded DNA and, with the cooperation of the 
MutL and the MutH proteins, it targets a section around the mutated DNA 
strand before removal. Other proteins complete the repair process: the 
section of DNA that is targeted is removed and degraded, the remaining 
single stranded DNA gap is filled in using the complementary strand as a 
template, followed by ligation resulting in a repaired section of double-
stranded DNA without mismatches. 
In the human MMR system the mismatch recognition function is fulfilled by 
a heterodimeric protein complex composed of two MutS Homologous 
(MSH) proteins. The major MSH dimer consists of MSH2 and MSH6, also 
called MutSα. This complex is able to bind to base-base mismatches and 
IDLs. A minor and partially redundant mismatch binding heterodimer 
(MUTSβ) consists of the MSH2 and MSH3 proteins and this complex binds 
to larger IDLs (1). In the mismatch repair process MutS heterodimers 
recognise mismatches in the DNA. Binding to these mismatches induces a 
conformational change for the MutS heterodimer, which allows the uptake 
of ATP and the signalling towards the MutL heterodimers, and thus 
subsequently initiating a downstream repair event.  
Heterodimers composed of human MutL Homologous (MLH) proteins, 
MLH1, PMS2 and MLH3, interact with the MSH2-containing DNA-protein 
complex and coordinate downstream repair events. These downstream 
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events involve different proteins such as exonucleases (e.g. EXO1) and 
DNA polymerases (13;14). The heterodimer MLH1-PMS2 (MUTLα) 
interacts with both MSH2-MSH6 and MSH2-MSH3, while the heterodimer 
MLH1-MLH3 (MUTLγ), appears restricted to interactions with only MSH2-
MSH3 (15;16). 
Another human MutL homologue, PMS1, has also been suggested to 
function in mismatch repair but a biochemical role for this protein in 
mismatch repair has not been demonstrated (17). Lipkin et al (15) have 
suggested that PMS1 as well as PMS2 and MLH3 may exhibit functional 
redundancy.  
In addition to its indispensable role in removing misincorporations, the 
repair proteins are involved in or have an influence on other processes, 
such as apoptosis and proliferation (18;19). MMR is also involved in 
determining cellular sensitivity to a number of DNA damaging agents. Some 
of these drugs are used as chemotherapeutics, e.g. the SN1 DNA 
methylating chemotherapeutics procarbazine, dacarbazine and 
temozolomide, the cross-linking chemotherapeutic cisplatin, and the 
immunosuppressant azathioprine (for reviews on this subject see (20-22)).  
 
1.4 Lynch syndrome and MMR 
As mentioned, the majority (>90%) of germline mutations found in Lynch 
syndrome patients affect one of two MMR genes, MSH2 and MLH1 (9). 
Five to ten percent of Lynch syndrome families carry a germline mutation in 
the MSH6 gene (23). PMS2 mutations were believed to be very rare in 
Lynch syndrome (24), although recently the number of reported mutations 
is rising (25). 
Two other MMR genes have been screened for mutations, namely MLH3 
and EXO1 (26-28). Germline mutations were indeed found in these genes, 
but at a low frequency and mostly representing missense mutations that 
cannot be classified directly as pathogenic. These genes are therefore not 
believed to be key players in Lynch syndrome (29-33). We postulate that 
mutations in these genes might modify the penetrance of the disease rather 
than being causative. There have been no reports on germline mutations of 
MSH3 in Lynch syndrome (9). 
 
 
Section 2   Identifying patients with MMR gene mutations 
 
2.1 Identifying patients with MMR gene mutations: introduction 
Identifying MMR mutation carriers is important as it opens avenues for 
families to undergo presymptomatic testing. Identifying MMR mutations 
greatly facilitates carriers as they can enrol in cancer surveillance 
programs, making it possible to detect tumours in early stages and offering 
the possibility of presymptomatic diagnosis in Lynch syndrome families. 
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Equally important, non-mutation carriers can be dismissed from these 
screening programs. Mutation detection is, however, hampered by the facts 
that the disease is heterogeneous, mutations are spread all over the genes, 
hardly any founder mutation is identified, and the fact that mutation 
detection is costly and labour-intensive. Rapid and accurate mutation 
detection in these genes is a technical challenge. So far, there is no single 
technique allowing the detection of all types of mutations that have been 
identified in Lynch syndrome families. Rather than testing all patients with 
colorectal cancer (or any other type of cancer that could be Lynch 
syndrome associated), criteria have been introduced to select patients that 
have relatively high chances of being MMR gene mutation carriers for 
further molecular analysis. Clinical as well as non-clinical criteria can be 
used for this preselection. 
 
2.2  Clinical criteria 
In 1991, the International Collaborative Group on HNPCC (ICG-HNPCC) 
proposed a set of criteria primarily for research purpose to clinically define 
Lynch syndrome and to make Lynch syndrome-related research more 
comparable (4) These criteria, also called the Amsterdam I criteria, define 
Lynch syndrome as follows: occurrence of histologically CRC in at least 
three relatives (one of whom is a fist-degree relative of the other two) in at 
least two successive generations, and in one of the relatives with colorectal 
cancer age at diagnosis is less than 50 years. Familial adenomatous 
polyposis should be excluded. The Amsterdam I criteria have contributed 
enormously to uniformity in the clinical diagnosis of Lynch syndrome. 
However, it should be noted, that the Amsterdam I criteria fail to 
acknowledge the contribution of extracolonic cancers and lead to an 
underdiagnosis of the syndrome. So in 1999, the Amsterdam II criteria were 
formulated (34), which also take in account this extracolonic cancers. 
Again it is argued that also the Amsterdam II criteria are too stringent, as a 
significant proportion of families carrying MMR germline mutations do not 
fulfil these criteria and will be excluded from cancer surveillance programs 
when the Amsterdam criteria for selection for mutation analysis are applied 
(35;36). 
To overcome this disadvantage of the Amsterdam criteria, several groups 
have proposed less restrictive clinical criteria, including the revised 
Bethesda criteria, the Japanese criteria, and the Mount Sinai criteria (9;37-
40). These criteria are dependent on both family history and clinical 
pathological characteristics of the tumour and on the association with 
extracolonic cancers. Of these the Bethesda criteria the best validated and 
thus are most used. Table 1 lists these criteria. Patients (or tumours from 
patients) meeting any of the revised Bethesda criteria, as well as tumours 
from family members, should be tested for microsatellite instability (MSI) 




Table 1. Revised Bethesda Guidelines for selecting Lynch syndrome related tumours that 
should be tested for MSI (for MSI see chapter 2.3). 
 
 Tumours from individuals should be tested for MSI in the following situations:       
 
    1. Colorectal cancer diagnosed in a patient who is less than 50 years of age.       
 
    2. Presence of synchronous or metachronous colorectal or other HNPCC-associated   
tumours,* regardless of age.       
 
    3. Colorectal cancer with the MSI-H histology  diagnosed in a patient who is less than 
60 years of age.       
 
    4. Colorectal cancer and one or more first-degree relatives with an HNPCC-related 
tumour, with one of the cancers being diagnosed under age 50 years.       
 
    5. Colorectal cancer diagnosed in two or more first- or second-degree relatives with 
HNPCC-related tumours, regardless of age.       
 
*Hereditary nonpolyposis colorectal cancer (HNPCC)-related tumours include colorectal, 
endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain 
(usually glioblastoma as seen in Turcot syndrome) tumours, sebaceous gland adenomas 
and carcinomas, keratoacanthomas in Muir–Torre syndrome, and carcinoma of the small 
bowel (48). Presence of tumour infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, 
mucinous/signet-ring differentiation, or medullary growth pattern.  
 
2.3  Microsatellite instability (MSI) analysis: 
MMR deficiency results in the accumulation of unrepaired mutations. 
Unrepaired mutations are easily detected by looking at repetitive 
sequences, the so-called microsatellites, as these sequences increased or 
decreased in length. This phenomenon is referred to as microsatellite 
instability (MSI). As determining MSI is simple and because the large 
majority (85-90%) of tumours from Lynch syndrome families show MSI 
(called MSI-high or MSI-H), MSI testing has been put forward as the 
selection criterion for mutation analysis.  
As mentioned, the MSI-H phenotype is caused by the loss of MMR 
function. This lack of MMR function is caused by the inactivation of both 
alleles of the same MMR gene. In Lynch syndrome patients one allele is 
inactivated by a germline event, the second, wild type, allele is inactivated 
in the tumour by a somatic event resulting in physical or functional loss. In 
sporadic colorectal cancer patients two somatic events have to take place. 
In most sporadic cases the mechanism of bi-allelic inactivation is MLH1 
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promoter hypermethylation (41). As the overall percentage of Lynch 
syndrome tumours among all MMR deficient tumours is quite small, it is still 
under debate whether population-based MSI screening in all colorectal 
carcinomas is effective.  
 
2.4  Immunohistochemical staining (IHC) of MMR proteins  
The examination of tumour tissues for the loss of expression of a MMR 
protein by immunohistochemical staining (IHC) is another method to 
prescreen tumours for a MMR deficient phenotype. Tumour tissues that 
demonstrate an absence of nuclear staining in the presence of a positive 
staining in the normal cells in the same section are presumed to have bi-
allelic loss (mutations) of the corresponding MMR gene. IHC analysis is 
now routinely applied for the detection of MSH2, MLH1, MSH6 and PMS2. 
Interestingly, loss of only MSH6 and loss of only PMS2 can be observed 
whereas loss of MSH2 is always accompanied by subsequent loss of 
MSH6 and similarly loss of MLH1 is always accompanied by loss of PMS2. 
It is widely accepted that this concomitant loss of MMR proteins is related to 
the stability of the proteins, a stability that is depending on heterodimer 
formation (42;43). Loss of MSH2 alone or loss of MSH6 alone or loss of 
PMS2 alone is an indication for the presence of a germline mutation in the 
respective gene. Loss of MLH1 in IHC can be caused either by a MLH1 
germline mutation plus a second somatic MLH1 mutation on the other allele 
or rarely by germline hypermethylation of one allele plus somatic 
hypermethylation of the second allele (in the tumour) (44) or by biallelic 
somatic MLH1 promoter hypermethylation in the tumour, as seen in most 
sporadic cases.  
According to recent large studies (45-49), IHC is at least equally valuable 
as MSI analysis for detecting potential germline mismatch repair gene 
mutation carriers. Hayashi and colleagues showed that the absence of 
expression of MLH1 or MSH2 had 100 percent specificity for predicting a 
MSI-H phenotype (42/42). The sensitivity of IHC for detecting a MSI-H 
tumour was 93.3 percent (42/45). The predictive value of normal expression 
of both of these proteins for predicting the MSS/MSI-L status was 98.8 
percent. (50).  
 
2.5   Identification of germline line mutation in a non-tumour tissue 
based way 
As mentioned, tumour tissues from Lynch syndrome mostly show MSI-H 
and negative immunohistochemical staining(s) due to a loss of a MMR 
protein. When tumour tissues are not available, selection based on these 
parameters can not be performed. Development of a pre-screening method 
based on non-tumour tissues would therefore in these cases be very 
useful. Fields and co-worker (51) describe such a test. They tested Epstein 
Bar Virus (EBV) transformed lymphoblastoid cell lines from MMR gene 
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mutation carriers on heterozygous MMR protein loss.This strategy is based 
on the hypothesis that individuals harbouring a truncated germline mutation 
will show a 50% reduction of the mutated MMR protein. It is this reduction 
that can be quantified by immunoblotting leading to the identification of 
MMR germline mutation carriers. The Fields method makes use of EBV-
transformed lymphoblastoid cell lines. Making such cell lines is costly and 
labour and time intensive. Whether this approach can be used on 
lymphoblasts directly, is yet unclear. 
 
Section 3   Pathogenicity of UVs 
 
3.1  Assessing pathogenicity of mutations in MMR –genes 
Finding a DNA variant is one, deciding whether this variant is pathogenic, in 
other words, is contributing to the disease phenotype, is something else. 
The decision is easily made for mutations that result in premature 
termination of translation and thus in loss of function. For mutations not 
leading to such a premature termination of translation this however is less 
straightforward. For sure this is the case for mutations that give rise to 
single amino acid substitutions (~10% of MSH2, ~30% of MLH1, and ~37% 
of MSH6 mutations), or small in-frame deletions (9). These mutations, with 
an unclear pathogenic nature, are often referred to as unclassified variants 
(UVs). The question, whether a UV contributes to the disease phenotype or 
merely represents a rare polymorphism, constitutes a major problem with 
obvious direct clinical consequences.  
Several criteria (52-54) are generally applied, usually in combination, to 
assess the possible pathogenicity of a missense mutation: (1) de novo 
appearance of a UV; (2) segregation of the UV with the disease within 
pedigrees; (3) absence of the UV in control individuals; (4) a change of 
amino acid polarity or size; (5) occurrence of the amino acid change in a 
domain which is evolutionary conserved between species and/or shared 
between proteins belonging to the same protein family; (6) effect of the UV 
in a functional assay or in an animal model. In case of cancer genetics one 
might add (7) loss of the non-mutated allele in the tumour (usually by a 
large deletion, loss of heterozygosity, LOH) and (8) loss of protein 
expression in the tumour. In case of Lynch syndrome MSI of the tumour is 
used as well. 
Previous inclusion of the UV in the increasing number of disease-specific 
mutation databases is also often considered. However, as most databases 
do not add any information besides the fact that the mutation was identified 
in a patient we recommend not to use this criterion. Several of the above 
mentioned criteria are sometimes difficult to score. Furthermore, one should 
be critical on some (53). For instance point 3, segregation of the mutation 
with the disease, can be caused by linkage disequilibrium of the UV with 
the real un-identified mutation. LOH and negative IHC and in case of Lynch 
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syndrome MSI are no direct evidence and results obtained might again be 
due to an unidentified mutation in the same gene or in its regulatory 
sequences.  
We, and many with us, therefore believe that final proof should come from 
fulfilment of a combination of criteria including criterion 6, the effect of a 
mutation in a functional assay or in an animal model.  
 
3.2  Functional assays for MMR proteins  
 
Most functional assays try to measure a specific effect which a possibly 
causative mutation (UV) has on the function of the mutated MMR protein. 
Assays have been applied to measure the capacity of two MMR-proteins to 
bind to each other (dimer-formation). These include pull down assays and 
yeast two hybrid assays or transient expression of the protein in a relevant 
MMR-deficient cell line to determine stability of the protein complex (55). 
Other assays have been applied to determine the intrinsic mismatch 
nucleotide dependent ATPase activity of MSH protein heterodimers (56) 
and as one might also anticipate that trafficking or the subcellular 
localisation of the mutated MMR protein is disturbed, assays have been 
developed to determine the subcellular localisation of the mutant proteins 
(57).  
Besides testing specific functions of the repair proteins, it seems logical to 
determine the repair capacity of the mutated protein as a whole. Assays 
have been set up in which a MMR-deficient yeast strain or human cell line 
were complemented with the missing protein. This is achieved by transient 
transfections of expression vectors harbouring the corresponding yeast or 
human CDNA (wild type or mutant variant)(58-60). Another approach is to 
restore MMR by adding to protein extracts of MMR deficient cell lines 
mutant MMR proteins (a cell free system) (59;61).   
 
 
Section 4   Aim of the thesis 
 
Identification of MMR-gene mutation carriers and enrolling mutation carriers 
in surveillance programs for the early detection of tumours, has shown to 
increase survival (62). Present prescreening methods are based on either 
family history (e.g. Amsterdam criteria) or tumour analysis. Unfortunately, 
tumours may not be available for analysis and the same is true for normal 
tissue (blood is commonly used) from affected relatives. We therefore tried 
to develop a lymphocyte-based screening method to predict the presence 
of particular mismatch repair gene mutations in patients (in case their or 
their relatives, tumours would be unavailable) or in healthy relatives (in 
case tumours as well as normal tissue DNA from their affected relatives 
would be unavailable) from families suspected for Lynch syndrome. 
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Although a substantial proportion of the nontruncating mutations/variants 
group might be pathogenic, their clinical importance is as yet uncertain. 
Microsatellite instability and immunohistochemistry for MMR-gene 
expression proved to be only partially helpful in deciding on pathogenicity. 
Classification of the pathogenicity of nontruncating mutations is important in 
itself for scientific reasons, but has also obvious consequences for patient 
selection for mutation analysis (e.g. the presence of an MMR protein coded 
by a gene with a missense mutation does not prove normal function of that 
protein) and for genetic counseling and presymptomatic testing options. 
This thesis aims at determining the clinical relevance of nontruncating 
variants in the DNA mismatch repair genes (MLH3 and MSH6) by different 
kinds of functional assays. It is also imperative that the interpretation of 
these variants should be coordinated and that this information is made 
available to as many qualified investigators and clinicians as possible. We 
therefore decided to compile a database containing all the available data on 
published MMR-UVs that have been functionally tested so far and that can 
be updated in the future. 
 
 
Section 5   Outline of the thesis 
 
In this thesis we describe the development of a (blood) leukocyte-based 
screening method to identify mismatch repair gene mutations in individuals 
that might be carrying a MMR gene mutation. We describe how we try to 
use quantitative protein and RNA levels to identify such germline mutation 
carriers (Chapter 2).  
In Chapter 3 we review the various functional assays described for the 
Lynch syndrome-associated MMR proteins. We, furthermore, report on the 
outcomes of these tests on UVs identified in patients diagnosed with or 
suspected of having Lynch syndrome. The database used in chapter 3 is 
described in more details in Chapter 4. The database we constructed is 
filled with all details concerning functional assays previously published for 
Lynch syndrome associated MMR mutant proteins.  
To evaluate the pathogenicity of missense mutations found previously by 
our group we have set up functional assays for both MSH6 and MLH3. In 
Chapter 5, functional assays are described that evaluate the pathogenicity 
of 11 MLH3 UVs. These mutations were previously found in patients 
suspected of Lynch syndrome. In Chapter 6, a functional assay is 
described to evaluate the pathogenicity of 5 MSH6 UVs found in patients 
suspected of Lynch syndrome. In Chapter 7 we discuss our findings and 
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Identifying a MMR gene mutation in persons or patients suspected for 
Lynch syndrome, also referred to as hereditary non-polyposis colorectal 
cancer (HNPCC), is costly and time consuming. Screening for mutations is 
therefore only performed in individuals at high risk and pre-screening of 
tumour tissue by immunohistochemistry staining is preferred to direct 
mutation analysis. When no tumour material is available, all Lynch 
syndrome-associated MMR genes need to be screened for mutations in 
patients and this diagnostic approach is even less efficient if only DNA from 
asymptomatic relatives is available as often multiple individuals need to be 
screened. In search of an alternative pre-screening approach we have 
tested a method that quantifies the amounts of MMR proteins in leukocyte 
cultures. It is based on the hypothesis that (1) in dividing cells MMR genes 
are unregulated and, therefore, the products of these genes are detectable, 
and that (2) individuals with a germline truncating mutation in a particular 
MMR gene show a reduced level of protein encoded by that gene.  
Methods  
Western blotting was performed on protein extracts isolated from 
uncultured and shortly cultured leukocytes (3 days of culturing). Carriers of 
truncating MLH1 or MSH2 mutations or patients carrying in-frame deletions 
(5 patients for each gene) and healthy controls were studied. Densitometric 
quantification of the protein bands corresponding to MLH1 and MSH2 was 
performed. Moreover, quantitative MLH1 and MSH2 mRNA analysis was 
performed. 
Results  
The MLH1 and MSH2 protein products could be detected in the cultured 
leukocytes and not in the uncultured cells. However, the mutated gene in 
proven mutation carriers could not be predicted from densitometric analysis 
of the MLH1 and MSH2 protein bands seen on the Western blots. 
Furthermore, our analysis showed that there is a wide variation in the 
expression levels of MLH1 and MSH2 both on the mRNA and the protein 
level in patients and controls. 
Conclusion  
Shortly cultured leukocytes express easily detectable levels of MLH1 and 
MSH2 protein. Because of the wide variation in protein levels observed 
within and between the groups of mutation carriers and controls, these 
levels cannot be used to predict the presence of a germline truncating 




Lynch syndrome, also referred to as hereditary non-polyposis colorectal 
cancer (HNPCC), is one of the most common hereditary cancer syndromes. 
It is an autosomal dominant disorder characterized clinically by increased 
risks to develop colorectal and endometrial cancer and a range of other 
tumours (1;2). It is caused by germline mutations in one of the DNA 
mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 (3-5). 
Lynch syndrome-associated tumours usually show microsatellite instability 
(MSI) as a manifestation of their MMR-deficiency (6;7), and loss of 
immunohistochemical (IHC) staining for the MMR protein encoded by the 
corresponding mutated MMR gene (8-10).   
Screening for germline MMR gene mutations in patients who have a 
personal or family history suggestive of Lynch syndrome is costly and time 
consuming. Screening for mutations is therefore usually restricted to those 
individuals that have tumours featuring the above mentioned 
characteristics.  
If, however, tumours are unavailable then this type of pre-screening to 
select for MMR gene mutation analysis is not an option and affected 
individuals are then usually offered mutation analysis. In some families 
suggestive of having Lynch syndrome, neither tumour material nor DNA 
from affected relatives is available for analyses. In those cases, MMR gene 
mutation analysis can be offered to (a number of) unaffected close relatives 
of the affected patients, but this approach is even less efficient than in 
affected patients with untested tumours. A pre-screening method in normal 
tissue might therefore be a welcome addition to the existing selection 
techniques. For this reason we wondered if measuring expression levels of 
the MMR genes or of the encoded proteins in blood leucocytes could help 
predicting the presence of truncating germline MMR gene mutations, as 
mutation carriers would be expected to produce less, theoretically 50%, of 
the corresponding MMR protein in their dividing normal cells. Although it 
has been recently demonstrated that not all autosomal genes normally 
have bi-allelic expression, this does appear to be the rule for the MLH1 
gene in lymphoblastoid cells (11). To the best of our knowledge, only a 
single paper has reported on such an approach. Fields et al. (12) 
demonstrated reduced levels of MMR protein in EBV transformed 
lymphoblastoid cell lines of known MMR gene mutation carriers. However, 
making EBV transformed cell lines is costly and time consuming. In the 
ideal situation we would like to analyse leukocytes directly. However, as 
MMR protein levels are possibly low or not present in non-dividing cells, we 
also opted for a short culture procedure as routinely used in cytogenetic 
laboratories. Using protein extracts and RNA isolated from both uncultured 
and cultured leukocytes we investigated whether differences in expression 
of the MMR proteins or RNA levels between known MMR gene mutation 
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carriers and controls could be determined. Furthermore, we studied 
whether the afore mentioned procedures could be used in our routine 
diagnostics for the identification of mutation carriers.  
 
 
Material and methods  
 
Patients and Controls  
Individuals included in this study are either proven MMR mutation carriers 
or healthy controls. We included 5 carriers of MLH1 and 5 of a MSH2 
pathogenic germline mutation. As a control group we included 10 
anonymous healthy individuals. Of these controls, blood from 5 individuals 
was used for uncultured leukocyte isolation and blood from 10 individuals 
for leukocyte culturing. The mutations tested are listed in Table 1. Among 
these mutations several deletion-mutations are present, all of which are 
considered pathogenic as either a whole exon or multiple exons are deleted 
or functional assays have been performed that showed pathogenicity (3 bp 
deletion in MLH1) (13). 
 
Leukocyte culturing 
Ten ml of heparinized whole peripheral blood was drawn from each of the 
selected individuals. For each individual 8 cultures were set up. Each 
culture was started by adding 0.5ml of heparinized whole blood to 10ml of 
RPMI 1640 medium (Invitrogen, Breda, the Netherlands) in a T25 flask with 
5% Fetal Calf Serum (Invitrogen, Breda, the Netherlands) and 0.1485 mg 
/ml of Phyto Haemaglutinin (Remel Inc. Lenexa, USA). The cultures were 
incubated at 37ºC in 5% CO2 atmosphere for 72 hours. Directly before and 
after culturing, the leukocytes were counted as an index on divisional 
activity. Out of these cultures leukocytes were isolated using a modified 
hypotonic method (protocol available upon request). 
 
Protein isolations 
Six of the eight T25 flasks of leukocyte isolations were used for protein 
isolations. Leukocyte pellets were lysed for 1 hour at 4ºC in 500 µl CelLytic 
TM
 M (mammalian cell lysis reagent; Sigma, Saint Louis, U.S.A) with one 
protease inhibitor tablet was added (1x final concentration; Roche, Basel, 
Switzerland). Lysates were stored at -80ºC. 
 
RNA isolation  
Total RNA was isolated out of two T25 flasks. The leukocyte pellets were 
added to 1 ml RNAbee (AMS Biotechnology Europe Ltd, Abingdon, Oxon, 
UK). Next, total RNA was isolated according to the manufacturer’s 
instructions and cleaned with the RNeasy MinElute Cleanup Kit (Qiagen 
Benelux B.V. Netherlands, Venlo, the Netherlands) to remove genomic DNA 
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contamination. RNA quality was evaluated with an Agilent 2100 Bioanalyzer 
(Agilent Technologies Netherlands B.V., Amstelveen, the Netherlands). First 
strand cDNA was prepared from 1 µg of total cellular RNA using random 
hexadeoxynucleotide primers and first strand cDNA synthesis ready to use 
beads (Amersham, GE Healthcare Europe GmbH, Diegem, Belgium).  
 
Western blot analysis for the detection of MMR protein 
100 µg of total protein extracts from uncultured or cultured leukocytes was 
separated on denaturing 6% SDS polyacrylamide gels and blotted onto 
nitrocellulose membranes (Bio-Rad, Veenendaal, the Netherlands). The 
following antibodies were used: anti-MSH2 (Catalog No. NA27, 
Calbiochem, La Jolla, USA; immunogen: a C-terminal fragment of human 
MSH2; 1:500 dilution); anti-MLH1 (clone G168-728, Pharmingen, Breda, 
the Netherlands; immunogen: full-length protein; 1:500 dilution); anti-mouse 
IgG HRP-conjugated secondary antibody (Pierce Biotechnology, Rockford, 
USA). Signal visualization was performed with the Supersignal West Dura 
Extended Duration Substrate kit (Pierce Biotechnology, Rockford, USA). 
ECL signals were visualized with a G:BOX Chemi HR16 automated image 
analyser (SYNGENE, Cambridge, UK) and unsaturated blot images were 
obtained by using the Genesnap software (SYNGENE, Cambridge, UK). 
Densitometric analyses of the signals was performed using the 
GENETOOLS software of the image analyzer 
 
Quantitative PCR  
Quantitative PCR was performed in a volume of 25 µl containing 1x iQ™ 
SYBR Green supermix (Bio-Rad laboratories B.V, Veenendaal, the 
Netherlands). SYBR Green fluorescence was measured real time during 
PCR (IQ 6 PCR, Bio-Rad Laboratories B.V, Veenendaal, the Netherlands). 
Quantitative PCR was performed in triplicate for MLH1 and MSH2 primer 
sets and the mean value was used as relative quantification. For 
normalization TBP (TATA box binding protein) was used. The primers used 
for MLH1 are: 5’-TGAGGTGAATTGGGACGAAGA-3’ and 
5’GTGTGAGCGCAAGGCTTTATAGA-3’; the primers used for MSH2 are: 
5’-GCTAAACAGAAAGCCCTGGAAC-3 and 5’- 
ACCTTGGACAGGAACTCCTGAAT-3’; the primers used for TBP are: 5’-












Culturing leukocytes  
The leukocyte number was counted directly before culturing and after 
culturing. The count number of leukocytes directly before culturing was 
approximately 2-3 x109/ml. After 3 days of culturing the number of cells had 
doubled (between 4 and 6 x109 /ml). 
 
Western blotting of MLH1 and MSH2 in control samples  
Western blotting on protein extracts from uncultured leukocytes from 
controls revealed no detectable signal for the MLH1 or MSH2 proteins 
(Figure 1). Western blotting of protein extracts isolated from cultured 
leukocytes from controls did show detectable levels of the MLH1 and MSH2 




Figure 1. Western-blot analysis for MLH1 and MSH2 in Leukocytes from control individuals. 
Lanes 1-5 are cultured leukocytes (three days of culturing), lanes 6-10 are loaded with 
protein extracts form uncultured blood leukocytes. The blot was probed with MLH1 and 
MSH2. 
 
MLH1 mutation carriers  
Figure 2 shows that the MLH1 protein levels of 5 proven MLH1 mutation 
carriers are decreased. The amounts of MLH1 for the 5 mutation carriers 
differed considerably. These samples (lanes 1-5) belong to individuals with 
pathogenic MLH1 mutations (lanes 1 & 2: EX16del; lane 3 p.Glu71del; lane 
4 p.Arg487X; lane 5 p.EX12FS, designated name details see table 1). As 
we expect that the ratio between the MLH1 and MSH2 protein should be 
constant (for proper repair) we used MSH2 for normalisation. We calculated 
the MSLH1/MSH2 ratio (see table 1 and figure 2 Beneath the MLH1/MSH2 
ratios are given). The ratio data show that these ratios vary (even between 





















Figure 2. Western-blot analysis for MLH1 and MSH2 in cultured leukocytes from MLH1 
mutation carriers (lane 1- 5) and in 3 healthy control samples (lane 7-9). The ratio between 
MLH1 and MSH2 (MLH1/MSH2) is given below the figure. 
 
MSH2 mutation carriers  
Figure 3 shows no significant differences for the MSH2/MLH1 ratio between 
MSH2 mutation carriers and healthy controls. In this experiment we used 
MLH1 for normalisation. As for MLH1, large variation in the level of 
expression among MSH2 mutation carriers or the healthy control group is 
observed.  
That the expression level of this protein is variable is further strengthened 
by the results obtained from three individuals harbouring the same MSH2 
mutation (lanes 1-3 Figure 3).   
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Figure 3. Western-blot analysis for MLH1 and MSH2 in cultured leukocytes from MSH2 
mutation carriers (lane 1- 5) and in 2 healthy control samples (lane 8-9). The ratio between 
MSH2 and MLH1 (MSH2/MLH1) is given below the figure.    
 
Additional controls for Western blotting  
As we did observe large deviations in the levels of protein expression of 
cultured leukocytes from both the MLH1 and MSH2 mutation carriers and 
the 3 controls, we analysed an additional 7 controls. The data obtained 
(Figure 4a) again illustrates that large variations in the eventual protein 
levels exist between individuals. 
 
Quantitative PCR on controls  
Quantitative PCR (Figure 4b) shows that the MLH1 expression levels in 7 
control samples, when normalised to the housekeeping gene TBP, show 
slight differences in expression, as all expression levels are within a 0.4 fold 
range. For MSH2 there was an about 5 fold difference between the highest 
levels and the lowest levels of expression. When we determined the 
MLH1/MSH2 ratios we also observed a 4.6 fold difference between the 





































Figure 4. A. Western-blot analysis for MLH1 and MSH2 in cultured leukocytes from 7 
healthy control samples. B. Quantitative real time PCR analysis of MLH1 and MSH2 mRNA 





In contrast to measurements in uncultured leukocytes, MLH1 and MSH2 
proteins could easily be detected in leukocytes cultured for 3 days 
according to a culture method routinely used in cytogenetics laboratories. 
However, due to a large variation in the eventual results within and between 
the groups of mutation carriers and controls in the level of these proteins, 
no reliable prediction could be made for the mutation status. Several factors 
could have contributed to the large intersample variability. These reasons 
could be technical. Western blotting is a semi-quantitative technique. 
Saturation of signals limits proper quantification. The variation might also be 
caused by differences in the functioning of the nonsense mediated RNA 
decay pathway (NMD pathway). The NMD pathway has been shown to 
degrade transcripts harbouring disease causing nonsense or frameshift 
mutations (14;15). However, NMD efficiency may vary considerably 
between different cell types and the treatment of those cell types (16-18). A 
wide variation in the abundancy of the MMR encoded protein between 
different individuals may be physiological. Yu et al. (19) recently observed 
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up to 4761.5 fold differences in MLH1 mRNA expression between normal 
colon tissues. Similar physiological differences may apply to other tissues, 
including leukocytes and might be the best explanation for our findings. 
Whatever the reason for the wide variation in protein levels within and 
between the groups of mutation carriers and controls and between cultures 
may be, presently, we cannot recommend this method as a practical clinical 
tool. 
 
Alternative pre-selection methods have been reported. Fields et al.. (12) 
demonstrated reduced levels of MMR protein in EBV transformed 
lymphoblastoid cell lines of known MMR gene mutation carriers. They also 
found large variation in the ratios between MSH2 and MLH1, as protein 
ratios range from 0.19 to 0.71 in truncated MSH2 germline mutation 
carriers. However, detailed data was not shown for their control group, so it 
is difficult to weigh these data with respect to the predictive power of this 
test for mutation status. In addition, the facility for making EBV-transformed 
cell lines may not be available in every lab. To the best of our knowledge 
this method has not been reported by other investigators or introduced in 
clinical laboratories as a patient selection tool for MMR gene mutation 
analysis. 
Another approach is the demonstration at the mRNA level of expression of 
one or both alleles of a particular MMR gene. This technique requires the 
presence of a polymorphism that can distinguish between the two alleles of 
each of the Lynch syndrome associated genes. This approach has been 
shown to work in some cases (18). However one needs informative coding 
markers in all MMR genes which might turn out difficult. In addition, NMD 
efficiency depends on the position of a mutation and therefore allelic 
imbalance may differ in all mutation carriers (18). Together, this limits the 
use of this approach in larger groups of Lynch syndrome suspected 
patients. 
 
In summary, we have demonstrated easily detectable levels of MLH1 and 
MSH2 proteins in shortly cultured leukocytes from MLH1 and MSH2 
mutation carriers and controls. However, these protein levels could not 
reliably predict mutation status. There is a clinical need for a method to 
select patients (or their relatives in case DNA from patients is unavailable) 
for mutation analysis when tumour tissue is unavailable. Presently, no such 
method for practical use on a larger scale is available. In the future this may 
pose less of a problem, as solid phase sequencing is getting cheaper and 
sequencing the Lynch syndrome-associated genes in a single experiment is 
becoming available. Therefore mutation analysis will become more 
affordable and can be applied to larger groups of individuals with less need 
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Functional analysis helps to clarify the clinical importance 
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Hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome is 
caused by DNA variations in the DNA mismatch repair (MMR) genes 
MSH2, MLH1, MSH6 and PMS2. Many of the mutations identified result in 
premature termination of translation and thus in loss-of-function of the 
encoded mutated protein. These DNA variations are thought to be 
pathogenic mutations. However, some patients carry other DNA mutations, 
referred to as unclassified variants (UVs), which do not lead to such a 
premature termination of translation and it is not known whether these 
contribute to the disease phenotype or merely represent rare 
polymorphisms. This is a major problem which has direct clinical 
consequences. Several criteria can be used to classify these UVs, such as: 
whether they segregate with the disease within pedigrees, are absent in 
control individuals, show a change of amino acid polarity or size, provoke 
an amino acid change in a domain which is evolutionary conserved and/or 
shared between proteins belonging to the same protein family, and their 
effects in a functional assay or animal model.  
In this review we discuss the various functional assays reported for the 
HNPCC-associated MMR proteins and the outcomes of these tests on UVs 
identified in patients diagnosed with or suspected of having HNPCC. We 
conclude that a large proportion of MMR UVs are likely to be pathogenic, 






Hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome is 
an inherited disorder caused by germline mutations in DNA mismatch 
repair (MMR) genes. Most of the mutations found in HNPCC patients affect 
one of two MMR genes, MSH2 or MLH1 (Peltomaki P., et al. ) while a small 
fraction of HNPCC families carry a germline mutation in the MSH6 gene 
[Berends et al., 2002]. PMS2 mutations were believed to be very rare in 
HNPCC [Lynch et al., 1997], however, recently the number of reported 
mutations has been rising [Hendriks et al., 2006]. 
 
Mismatch Repair System 
The mutated genes found in HNPCC patients all encode proteins that are 
part of the MMR system, which comprises an evolutionary conserved set of 
proteins to recognize and remove replication errors that escape the 
proofreading activities of replicative DNA polymerases, thereby providing a 
back-up system for the polymerases’ proofreading. The MMR system 
corrects not only mispaired nucleotides but also small insertion/deletion 
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loops resulting from slippage of the replicative polymerases during 
replication of microsatellites consisting of mono- or di-nucleotide repeats. 
The ability of many species to repair mismatches in double-stranded DNA 
has been well documented. The first critical step in this process is the 
recognition of the mismatched DNA. In the Escherichia coli MMR system - 
still the best documented - the MutS protein accomplishes this initial step. A 
homodimer of the MutS protein binds to the site of a mismatch in double-
stranded DNA and, with the help of the MutL and MutH proteins, targets a 
section around the mutated strand before removal. Other proteins complete 
the repair process: the target section of DNA is removed and degraded by 
exonucleases, the remaining single-strand DNA gap is filled by polymerase 
using the complementary strand as a template, followed by ligation that 
results in a repaired section of double-stranded DNA without mismatches. 
In the human MMR system the mismatch recognition function is fulfilled by 
a heterodimeric protein complex composed of two MutS Homologous 
(MSH) proteins. The major MSH dimer consists of MSH2 and MSH6, also 
called MutSα. This complex is able to bind to base-base mismatches and 
insertion/deletion loops. A minor and partially redundant mismatch binding 
heterodimer (MUTSβ) consists of the MSH2 and MSH3 proteins and this 
complex binds to larger insertion/deletion loops [Chung and Rustgi, 2003]. 
In the mismatch repair process, MutSα recognizes mismatches in DNA. 
Binding to this mismatch induces a conformational change for MutSα, 
which allows ATP to bind, attract the MLH1/PMS2 heterodimer and then 
initiate the downstream repair event. The repair proteins are, however, also 
involved in, or at least have an influence, on other processes, such as 
apoptosis and proliferation [Shin et al., 1998; Jiricny, 2006]. 
Heterodimers composed of human MutL Homologous (MLH) proteins - 
MLH1, PMS2 and MLH3 - interact with the MSH2-containing DNA-protein 
complex and coordinate the downstream repair events. These downstream 
events involve different proteins such as exonucleases (e.g. EXO1) and 
DNA polymerases [Tishkoff et al., 1997; Tran et al., 2001]. The heterodimer 
MLH1-PMS2 (MutLα) interacts with both MSH2-MSH6 and MSH2-MSH3, 
while the heterodimer MLH1-MLH3 (MutLγ), appears to be restricted to 
interact with only MSH2-MSH3 [Flores-Rozas and Kolodner, 1998; Lipkin et 
al., 2000a]. Another human MutL homologue, PMS1, has been suggested 
to also have a role in mismatch repair, but a biochemical role for this 
protein has not been demonstrated in mismatch repair [Marsischky et al., 
1996]. Lipkin et al. [2000] suggested that PMS1, PMS2 and MLH3 may 
exhibit functional redundancy. 
In addition to its indispensable role in removing misincorporations, MMR is 
also involved in determining cellular sensitivity to a number of DNA 
damaging agents. Some of these agents are used as chemotherapeutic 
drugs (procarbazine, dacarbazine and temozolomide methylate SN1 DNA, 
cisplatin is cross-linking, and azathioprine is an immunosuppressant) (for 
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recent reviews on this subject see [Buermeyer et al., 1999; Schofield and 
Hsieh, 2003; Stojic et al., 2004]).  
 
Disease Associated Mutations 
DNA variations that result in premature termination of translation, and thus 
in loss-of-function, give rise to HNPCC and are thought to be pathogenic 
mutations. For DNA variants that do not lead to such a premature 
termination of translation, this is however less straightforward. This is 
certainly the case for DNA variants that give rise to single amino acid 
substitutions (~10% of MSH2, ~30% of MLH1, and ~37% of MSH6 
variants), or small- or large in-frame deletions (~10% of both MSH2 and 
MLH1 variants see http://www.insight-group.org). These DNA variations, 
with an unclear pathogenic nature, are often called unclassified variants 
(UVs).  
Whether an UV contributes to the disease phenotype or merely represents 
a rare polymorphism constitutes a major problem with direct clinical 
consequences for HNPCC patients [Syngal et al., 1999; Cravo et al., 2002]. 
Pathogenic mutation carriers have a high cancer risk and should therefore 
be monitored regularly to detect neoplasias at the earliest possible stages. 
Presymptomatic testing can be offered to all (adult) family members who 
carry pathogenic mutations and those who are not carriers can be released 
from cancer surveillance programs.  
Several criteria [Hofstra et al., 1997; Cotton and Scriver, 1998; Syngal et 
al., 1999] can be applied, usually in combination, to assess the possible 
pathogenicity of a UV: (1) de novo appearance, (2) segregation with the 
disease within pedigrees, (3) absence in control individuals, (4) a change of 
amino acid polarity or size, (5) occurrence of the amino acid change in a 
domain which is evolutionary conserved between species and/or shared 
between proteins belonging to the same protein family, and (6) effect in a 
functional assay or in an animal model. In the case of cancer genetics, we 
could add: (7) loss of the non-mutated allele by a large deletion (loss-of-
heterozygosity, LOH), and (8) loss of protein expression. In the case of 
HNPCC, microsatellite instability of the tumour is sometimes used as well. 
Previous inclusion of the UV in the increasing number of disease-specific 
mutation databases is also often considered a valid argument for 
pathogenicity but, since most databases do not add any information 
besides the fact that the mutation was found in a patient, we do not 
recommend using this criterion. Several of the above criteria can be difficult 
to score and some may be unreliable [Hofstra et al., 1997]. For instance 
point (3), the mutation segregating with the disease can be caused by the 
UV being in linkage disequilibrium to the true, as yet unidentified mutation. 
LOH and negative immunohistochemistry and, in the case of HNPCC, 
microsatellite instability do not provide direct evidence, and again the 
results obtained might be due to an unidentified mutation in the same gene 
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or in its regulatory sequences. 
We therefore believe that we should look for final proof via criterion 6, the 
effect of a mutation in a functional assay or in an animal model.  
Our aim was to review the functional assays reported for the HNPCC-
associated MMR proteins and to discuss the outcomes of these tests on 




Functional Assays for MMR Proteins  
 
Most functional assays are designed to measure a specific effect that 
potentially causative mutations (UVs) may have on the biological or 
biochemical function of the mutated MMR protein. 
A properly functional MMR system needs to perform a wide range of steps: 
produce proteins; transport to the nucleus; bind different protein-complexes 
at the site of the DNA mismatch all of which may result in repaired 
mismatches. It should therefore not come as a surprise that many of these 
steps have been made the focus of functional analysis. Such assays 
determine the capacity of two MMR-proteins to form protein-protein 
complexes (dimer formation) and commonly used assays include pull-down 
and yeast two-hybrid assays, or transient MMR gene expression in relevant 
MMR-deficient cell lines to determine stabilization of the endogenous or 
exogenous binding partner [Raevaara et al., 2005„]. Some assays have 
also been applied to reveal ADPATP cycling by MSH protein dimers 
[Heinen et al., 2002]. It is also possible that intracellular trafficking or the 
subcellular localization of the mutated MMR protein is disturbed, so that 
determining the subcellular localization of the mutant protein in the cell 
seems an obvious course of action [Nielsen et al., 2004; Brieger et al., 
2005]. 
Besides testing distinct properties of the repair proteins, it seems logical to 
determine whether the mutated protein can restore repair capacity in MMR-
deficient cells or cell extracts. Assays have been developed in which MMR-
deficient yeast or human cells were complemented with an exogenous 
expressed MMR gene or genes and the overall repair capacity could be 
measured [Holmes, Jr. et al., 1990; Drotschmann et al., 1999; Trojan et al., 



































Subclassification Specific functional assay # Feature Disadvantages 
Yeast two-hybrid assay (IA) # Measures the physical interaction (in vivo) 
between two MMR proteins in yeast 
Tests only one specific feature of the MMR 
protein (heterodimer formation) 
Tests only mutations involved in the physical 
interaction  
False-positive or -negative problem 
Glutathione S-transferase (GST) pull-
down assay (IB) 
Measures the physical interaction (in vitro) 
between two MMR proteins  
Tests only one specific feature of the MMR 
protein 
Tests only mutations involved in the physical 
interactions  
False-negative results  
Measures the capacity of 
two MMR proteins binding 
to each other 
(heterodimer formation) 
Transient expression of MMR genes in 
relevant MMR deficient cell line (IC) 
Measures protein stability (in vivo) between two 
MMR proteins 
Tests only one specific feature of the MMR 
protein (stability)  
High concentrations of protein might be toxic 
DNA mobility shift assays (gel shift 
assay) (ID) 
Measures the capacity of two MMR proteins (a 
heterodimer) to recognize and bind mismatched 
DNA (in vitro)  
Tests only one specific feature of the MMR 
protein (DNA binding) 
The label for visualization could potentially 
interfere with the DNA-protein interactions  
Heterodimer binding to 
mismatched DNA 
Binding to immobilized DNA (1D) Measures the capacity of MMR heterodimers to 
recognize and bind mismatched DNA on the 
surface of a biosensor (in vitro) 
Tests only one specific feature of the MMR 
protein (DNA binding) 
ATP↔ADP cycling ATP binding, ATP→ADP exchange, 
ATP-induced dissociation from a 
mismatch, etc. 
Tests ATPase catalytic efficiency, ATP binding, 
ATP→ADP exchange, conformational change in 
the presence of ATP and efficiency of loading 
multiple sliding clamps on to a circular DNA strand 
Only tests on the MutS proteins (restricted to 
MSH2) 
Group I 




function of a 
MMR protein 
MMR protein subcellular 
localization 
Localization experiments (IF) 
 
Expression of fluorescent MMR proteins in 
mammalian cells to localize the distribution of 
these proteins in the cell 
Overexpression of MMR proteins might 
interfere with proper localization  
Overexpression of MMR proteins might be 
toxic 
 
Expression of mutant yeast MMR genes 
in haploid yeast strains (IIA-1) 
Expression of mutant human MMR 
genes in haploid yeast strains (IIA-2) 
Functional assays using 
yeast (IIA) 
Expression of mutant yeast MMR genes 
in diploid yeast strains (IIA-3) 
Expression of mutant human or corresponding 
yeast MMR in yeast strains to monitor the repair 
capacity as a whole (based on the homology of 
human and yeast MMR proteins) 
Only tests mutations occurring in evolutionary 
conserved regions between human and yeast 
The use of a heterologous system may result 
in artifacts 
 
Functional assays using 
cell-free systems  
Cell-free in vitro MMR assays (IIB) Tests in vitro the repair of mismatched DNA by 
protein extracts. Mostly baculovirus infected insect 
cell extracts are used to complement MMR-
deficient cell extract 
The ratio between the substrate and the 
proteins added to in vitro MMR assay is 
critical.  
Does not measure defects in splicing, protein 





capacity as a 
complete 
process 
Functional assays using 
human cell lines  
Cell based in vitro MMR functional assay 
using a human expression system (IIC) 
Expression of mutant human MMR genes in 
homologous human cell lines to monitor the repair 
capacity as a whole 
Human cell lines are sometimes difficult to 
transfect 
Expression level (and ratios) are critical  
May not be sensitive to defects in splicing, 
intracellular localization, etc. 
Overexpression of MMR proteins might be 
toxic  
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Group I. Tests for a specific biological or biochemical function of an 
MMR protein 
 
Yeast Two-Hybrid Assay (referred to as Assay IA in Tables 1-5) 
The yeast two-hybrid assay can be used to measure the physical 
interaction between two proteins. In this assay one of the proteins of 
interest (e.g. MSH2) is fused to a DNA-binding domain of a transcription 
factor (e.g. GAL4), whereas its interacting partner (e.g. MSH6) is fused to 
the DNA activation domain of the same transcription factor. If the two 
proteins of interest interact, the DNA binding domain and activation domain 
are brought into each other’s proximity upon which they are able to activate 
the transcription of a reporter gene or genes (e.g. His3, or LacZ). In 2003, 
for instance, Kondo et al. [2003‚] used this assay to show that 18 of 23 
(78%) of the tested MLH1 missense mutations disrupt proper protein 
binding and might therefore be considered as causative for HNPCC. 
GST Pull-Down Assay (Assay IB) 
The glutathione S-transferase (GST)-fusion interaction (pull-down) assay is 
a different approach to measuring the physical interaction between two 
proteins. It is an in vitro technique that consists of a fusion-tagged ‘bait’ 
protein for which a binding partner (i.e. the ‘prey’) is being sought. In most 
cases, a GST-tagged bait protein is bound to an immobilized glutathione 
support, after which a labeled potential interacting partner, the prey (in vitro 
transcribed and translated) is added. If interaction occurs, the labeled 
protein can be visualized. Guerrette et al. [1999] used this assay to show 
that 9 of 11 (82%) MLH1 UVs displayed reduced binding to PMS2. 
Both the yeast two-hybrid assays and the GST pull-down assays are based 
on the physical interaction between two MMR proteins, such as MSH2 and 
MSH6. Both systems can only analyze variants that interfere with proper 
binding and will not, therefore, detect all the possible functional defects of 
the mutant protein being investigated. 
 
Transient Expression of MMR Genes in Relevant MMR-Deficient Cell Lines 
(Assay IC) 
Some of the MMR proteins need binding with an MMR protein partner to 
stabilize their expression. Brieger et al. [2002] showed that the MSH6 
protein became detectable in LOVO cells (cells carrying homozygous 
mutations in MSH2 resulting in destabilization of MSH6), after transfection 
with wild-type MSH2. In contrast, the MSH6 protein was not detectable in 
LOVO cells when some mutant MSH2 proteins were expressed (like 
hMSH2 Cys697Arg). These data indicate a defect in MSH2-MSH6 





DNA Mobility Shift Assays (Assay 1D) 
The capacity of MSH-dimers (MSH2-MSH6 or MSH2–MSH3) to bind to 
mismatched DNA can be measured directly by using an affinity sensor or by 
electrophoretic mobility shift assay (EMSA). This assay is based on the 
observation that complexes of protein and mismatch-containing DNA 
oligonucleotides migrate through a non-denaturing polyacrylamide gel more 
slowly than free oligonucleotides. EMSA has been used to test the binding 
capacity to mismatched oligonucleotides of MutSα proteins extracted from 
baculovirus or from yeast strains overexpressing these genes, with or 
without a missense mutation [Clark et al., 1999; Drotschmann et al., 1999]. 
Alternatively, a biosensor can be used to measure mismatch binding of 
MSH2 UVs [Heinen et al., 2002]. 
 
The MutS ADP-ATP Cycle (Assay 1E) 
Apart from testing the capacity of the heterodimer to bind mismatched DNA, 
assays for investigating other biochemical behaviors of MutSα mutants 
have been set up. An example is the mismatch binding-dependent 
ADPATP exchange which triggers a conformational change of MutS, 
resulting in a so-called ‘sliding clamp’ on the DNA. Heinen et al. [Heinen et 
al., 2002] examined seven missense mutations for mismatch binding (see 
1D) and for: (a) intrinsic ATPase activity, (b) ATP-binding activity, (c) 
ADPATP exchange, and (d) the efficiency of loading multiple MutS 
heterodimers on to circular DNA as a measure of sliding clamp formation. 
These assays showed that 6 of the 7 missense mutations cause a reduced 
molecular switch function of the mutant MSH2-MSH6 compared with the 
wild-type MSH2-MSH6 complex [Gradia et al., 1997; Fishel, 2001]. 
 
Protein Localization Experiments (Assay IF) 
Mutations in MMR proteins can affect other functional aspects of the 
proteins, including transcription, splicing and translation, protein stability, 
post-translational modification, and subcellular localization. Clearly, MMR 
proteins need to be transported to the nucleus to reach their target, the 
damaged DNA. The regulation of the subcellular localization of MMR 
proteins, although important for their function, is still poorly understood. It 
has been shown that the regulation of MMR protein localization depends on 
(a) specific sequences in the MMR proteins that interact with factors known 
to be involved in the nuclear import of proteins; as well as on (b) sequences 
involved in translocation of the protein to the nucleus, and on (c) specific 
protein-protein interactions in the MMR complexes [Brieger et al., 2005]. 
Subcellular localization of mutant MMR proteins can be investigated by 
immunostaining or by expressing fluorescent fusion proteins in mammalian 
cells and subjecting them to fluorescent microscopy. Raevaara et al. 
[Raevaara et al., 2005] found that an MLH1 mutant (D63E) was indeed 
unable to translocate to the nucleus.  
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Group II. Tests of MMR repair capacity as a complete process 
 
Functional Assays using Yeast (Assays IIA1-IIA3) 
Yeast-based functional assays have been developed based on the fact that 
the MMR system is evolutionary conserved. By replacing an evolutionary 
conserved amino acid with its mutated counterpart, we should be able to 
find out whether this replacement indeed has functional consequences. The 
system has been used mainly for analyzing mutations in MLH1, but there 
are limits to its use. As the human and the yeast MLH1 protein only share 
significant homology in the N- and C-termini, only mutations located in 
these regions can be analyzed. At least three different strategies have been 
used: (a) expression of the mutant yeast MMR gene in a haploid yeast 
strain deficient for the same MMR gene; (b) expression of a human MMR 
gene in a haploid WT yeast strain: this approach makes use of the 
dominant negative effect that wild-type human MMR proteins have in these 
cells; and (c) expression of a mutant yeast MMR gene in a diploid yeast 
strain containing only one functional allele of the same MMR gene. 
Although defects found in yeast-based functional assays are indicative of 
an UV’s pathogenic nature, we cannot excluded the fact that functional 
differences between yeast and human MMR may cause artificial results. 
 
a. Expression of Mutant Yeast MMR Genes in Haploid Yeast Strains (Assay 
IIA-1) 
Shcherbakova et al. [1999] introduced six missense mutations into the 
yeast mlh1 gene. All six were analogous to mutations identified in HNPCC 
patients. The mutants were integrated and expressed in a wild-type haploid 
strain (by homologous recombination), and when the spontaneous mutation 
rates of the mlh1 mutants were compared with a mlh1-deleted mutant they 
showed a mutation rate similar to that of the mlh1-deleted yeast haploid 
strain, for all six mutants. Shcherbakova et al. therefore concluded that all 
six MLH1 missense mutations were likely to be pathogenic. 
b. Expression of Mutant Human MMR Genes in Haploid Yeast Strains 
(Assay IIA-2) 
Clark et al. [2000] examined the mutation rate in an msh2 mutant yeast 
strain. They showed that expression of the human MMR proteins, alone or 
in combination, did not reduce the mutation rate in this mutated yeast 
strain. Thus, the human genes are not functional in yeast. Furthermore, 
expressing the individual human proteins in a wild-type yeast strain did not 
induce an increased mutation rate. On the other hand, expressing both 
wild-type human MSH2 and MSH6 in a wild-type yeast stain did increase 
the mutation rate enormously (4000-fold). Co-expression of human MSH2 
and MSH3 elevated the mutation rate (only) 5-fold, reflecting the minor role 
of the latter complex in MMR. The authors showed that the human MMR 
proteins bind to mismatched DNA, suggesting that in vivo the human 
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MutSα and MutSβ complexes compete with the yeast MMR heterodimers, 
thereby preventing correction of replication errors. This is called a 
‘dominant mutator effect’.  
In another study Shimodaira et al. [1998] showed that human MLH1 in 
MMR-proficient yeast behaved differently to the human MSH2 described by 
Clark et al. [2000], as human MLH1 on its own was sufficient to cause a 
dominant mutator phenotype. Both authors showed that certain MLH1 
missense mutations identified in HNPCC patients, could partially or 
completely abolish the dominant negative mutator effect indicative of the 
pathogenic nature of the mutant MLH1 genes. 
 
c. Expression of Mutant Yeast MMR Genes in Diploid Yeast Strains (Assay 
IIA-3) 
Drotschmann et al. [1999] showed that in yeast the combination of any of 
five mutant yeast MSH2 genes (under their natural promoter) and a wild-
type yeast MSH2 gene resulted in a mutator phenotype. This likely reflects 
a dominant mutator effect exerted by the mutant MutS dimers: as an 
example, introduction of the MSH2 G693A mutant into a diploid yeast strain 
containing only one functional MSH2 allele dramatically elevated the 
mutation rate (74-fold). The authors concluded that this result might explain 
why the corresponding heterozygous mutation in this patient was 
associated with early onset of colon cancer. 
Several methods have been applied to evaluate the mutation rates in yeast 
strains containing mutant MMR proteins, most of which make use of 
reporter genes. These reporter genes serve as selection markers; when 
mutated they lose or regain their function and can be used to determine the 
MMR capacity of the added mutant MMR protein [Tran et al., 1997; 
Polaczek et al., 1998; Shimodaira et al., 1998]. 
 
Cell-Free in vitro MMR Assays (Assays IIB) 
To measure the DNA repair capacity of a mutant MMR protein, protein 
extracts from a MMR defective cell are complemented with the missing 
(mutant) MMR protein [Holmes, Jr. et al., 1990; Li and Modrich, 1995]. 
Repair of artificial substrates containing a mismatch can be determined by 
the use of appropriate restriction enzymes that uniquely cleave repaired 
molecules. Optimal repair is seen when both proteins of a heterodimer 
complex are added. Li et al. [1995], for instance, showed that protein 
extracts of H6 cells that were deficient for MLH1 could regain their repair 
function when complemented with the human MutL homologues MLH1 and 
PMS2. Another example was reported by Nystrom-Lahti et al. [2002] who 
tested several MLH1 mutations found in HNPCC patients. The proteins 
were expressed in SF9 insect cells transfected with recombinant 
baculoviruses encoding mutant MLH1 cDNAs, followed by testing of the 
functional activity of the mutant proteins in vitro. They found that all the 
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mutants but one showed loss-of-function. One missense mutation MLH1 
S93G was still functional in this in vitro MMR assay, although the missense 
mutation segregated with the disease. The latter mutant may be defective 
in processes like mRNA splicing or intracellular transport of the protein, but 
these processes are not assayed in the procedure used. 
 
Cell-Based In vitro MMR Functional Assay using a Human Expression 
System (IIC) 
A functional assay described by Trojan et al. [2002] is based on transient 
transfection of a MLH1 mutant together with wild-type PMS2 in the (human) 
293T cell line, a cell line that is MLH1-deficient due to MLH1 promoter 
methylation (resulting in degradation of endogenous PMS2). Extracts from 
transfected cells were incubated with bacteriophage M13 DNA containing a 
mismatch in the LacZ α-complementation domain. After incubation, these 
heteroduplexes were introduced into suitable E. coli cells and their repair 
efficiency was measured by the number and color of the resulting plaques. 
This system enabled pathogenic mutations in MLH1 to be detected. 
If we compare functional assays based on the use of human cell lines and 
human proteins with those that are yeast-based, the human systems have 
several advantages: they permit the study of protein/protein interaction of 
any two known components of the human MMR system, and testing of all 
mutations, irrespective of their evolutionary conservation status [Nystrom-
Lahti et al., 2002] or position in the protein [Shimodaira et al., 1998; 
Nystrom-Lahti et al., 2002]. Human systems can give answers to questions 
of not only protein interaction but also on the repair procedure as a whole 
[Nystrom-Lahti et al., 2002]. 
 
 
Functionally Tested MMR UVs 
 
The mutation database set up by the International Society for 
Gastrointestinal Hereditary Tumours (www.insight-group.org) gives an 
overview of most of the MMR mutations published. It contains information 
on more than 400 mutations found in over 700 HNPCC kindreds [Peltomaki 
and Vasen, 2004]. However, the database does not provide details about 
any functional assays that may have been performed. Particularly we need 
additional information for the UVs to be able to decide whether or not these 
are pathogenic. We therefore decided to compile a database containing all 
the available data on published MMR-UVs that have been functionally 
tested. Tables 2-5 show the UVs and functional assays performed for 
human MLH1, MSH2, MSH6 and PMS2, respectively.  
Several points should be kept in mind: (1) There is a clear bias in the 
mutations tested. The majority of the tested mutations are missense 
mutations that were identified in patients with an MSI-H tumour. (2) 
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Sometimes clinical data (and MSI data) are not given, which makes 
genotype-phenotype correlations impossible. It is therefore impossible to 
answer questions such as whether pathogenic missense mutations always 
give rise to MSI-H tumours. (3) The type of functional assays used has 
changed over the years. Before 1999 almost all functional assays were 
yeast-based or used pull-down assays, and most of them were used to 
study only MLH1 and MSH2 variants. After 1999 more and more 
publications describe in vitro MMR assays or (human) expression systems 
for analyzing repair capacity as well as the subcellular localization of the 
mutant proteins [Trojan et al., 2002; Raevaara et al., 2005]. This trend 
reflects the notion that mismatch repair is involved in different biochemical 
events and a good functional assay should permit the whole repair process 
to be measured, including mechanisms such as gene expression, mRNA 
splicing, protein stability and protein localization [Trojan et al., 2002; 
Raevaara et al., 2005]. Since 2002 MSH6 UVs have also been analyzed.  
From the studies presented in Tables 2, we can conclude that a high 
percentage of tested UVs is likely to be pathogenic. For MLH1 49/70 (70%) 
of the UVs were considered to be pathogenic mutations in different 
functional assays. For MSH2 this was 25/35 (71%), while for MSH6 it was 
only 1/8 (13%). However, we cannot exclude the fact that these 
percentages may be skewed due to the ascertainment bias described.  
   
Table 2: Percentage of UVs considered pathogenic after functional testing 
 
Outcome functional assays % pathogenic 
UVs 





MLH1 70 21 49 70% 
MSH2 35 10 25 71% 
MSH6 8 7 1 13% 
PMS2 3  3 100% 
 
 
Although most data are consistent, there are some discrepancies between 
the results reported from different functional assays. For example, K618A 
(MLH1) (expressed in vitro) was examined for its ability to interact with 
PMS2 in a GST pull-down experiment [Guerrette et al., 1999]. It was shown 
that this UV gave rise to a significant loss-of-interaction (>85%). But the 
same UV was tested by another group [Raevaara et al., 2005] using a cell-
free in vitro MMR system and they found that it behaved similarly to wild-
type MLH1. Besides this UV, there were six other missense mutations for 
which discrepancies between assays were reported (see Supplementary 
Tables S1-S4, contradictory results marked with **; available on line at 
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http://www.interscience.wiley.com/jpages/1059-7794/suppmat. It is 
interesting to note that three out of the seven contradictions showed loss-
of-function in a protein-protein interaction assay (IB), or functional assays 
using yeast (IIA), but no loss-of-function in cell-free in vitro MMR assays 
(IIB). As the repair function seems to be intact, we could argue that this 
assay would likely be reliable. However, although in vitro MMR assays 
analyze the repair process as a whole, the ratio between the substrate and 
the proteins added to the in vitro MMR assay is critical and such a 
conclusion may not be justified [Trojan et al., 2002].  
Although there may be some bias in the data we chose to include, the 
tables clearly show that missense mutations do play an important role in 
HNPCC. Apart from this being important news for patients and their 
families, it should also make us reconsider the inclusion criteria for mutation 
analysis, as some of them are based on finding truncating mutations. For 
example, to date, we generally consider a combination of a positive family 
history, an MSI-H status, and negative staining for an MMR protein in 
immunohistochemical analysis as predictors and inclusion criteria for MMR 
mutation analysis [Reyes et al., 2002; Umar et al., 2004]. Clearly, missense 
mutation carriers would be excluded as the immunohistochemical staining 
would very likely be positive. Furthermore, some publications have shown 
that certain missense mutations (like E578G in MLH1) do not correlate with 
MSI [Liu et al., 1999].  
A database containing detailed information on all the UVs tested can be 
found on http://www.mmrmissense.org. 
 
 
Limitations of Functional Assays 
 
All the assays described here investigate aspects of MMR protein function, 
but UVs that do not cause any functional defect in the protein may still 
cause MMR defects, e.g., as a consequence of aberrations in mRNA 
splicing or stability [McVety et al., 2006]. Thus, we must emphasize that 
even if no obvious defects are found using a functional assay, pathogenicity 
can still not be excluded. Inother words, UVs that do not display a clear 
functional defect should not directly be considered to be polymorphisms. 
Also, when assay results predict a pathogenic nature of a variant, one 
should realize that it is of the utmost important that the proper positive and 
negative controls were included in the study. Besides these controls the 
expression level of the transfected proteins should also be kept in mind as 
high levels of these proteins might be toxic or could disturb normal 
functioning of the overexpressed protein. Further, when only part of the 
protein is expressed, this might also lead to findings that do not reflect 
reality (which is not the case in the assays described here). 
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Possibly the biggest problem of functional assays is the fact that the 
sensitivity and specificity has been determined for very few of the assays. 
As long as a test is not validated, results should be utilized with great 
caution and one might even argue that functional assays cannot be used to 
classify variants with any confidence in the absence of other (genetic) data. 
Finally, as already mentioned, DNA variants in the coding sequence might 
give rise to aberrant splicing as previously shown and this should be kept in 
mind (e.g., as described by Auclair et al. [2006] and Pagenstecher et al. 
[2006]).These limitation clearly show that refinement of the functional 





How to best screen the UVs for function is still under debate. At the 
moment, yeast and human cell systems are used, and different biochemical 
properties can be determined. Since pathogenic non-truncating alterations 
in MMR proteins may interfere with different biochemical mechanisms, it 
seems reasonable to combine different functional assays, especially those 
employing human homologous expression systems and those that 
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Germline mutations in the mismatch repair (MMR) genes MLH1, MSH2, 
MSH6 or PMS2 can cause Lynch syndrome. This syndrome, also known as 
hereditary nonpolyposis colorectal cancer (HNPCC), is an autosomal 
dominantly inherited disorder predominantly characterized by colorectal and 
endometrial cancer. Truncating MMR gene mutations generally offer a clear 
handle for genetic counselling and allows for pre-symptomatic testing. In 
contrast, the clinical implications of most missense mutations and small in-
frame deletions detected in patients suspected of having Lynch syndrome 
are unclear. We have constructed an online database 
(www.mmrmissense.org ) for information on the results of functional assays 
and other findings that may help in classifying these MMR gene variants. 
Ideally, such mutations should be clinically classified by a broad expert 
panel rather than by the individual database curators. In addition, MMR 
gene mutation databases could be interlinked or combined to increase 
user-friendliness and avoid unnecessary overlap between them. Within the 
community of the International Society for Gastrointestinal Hereditary 






Lynch syndrome and the need for missense mismatch repair gene mutation 
databasing. Germline mutations in the mismatch repair (MMR) genes 
MLH1, MSH2, MSH6 or PMS2 can cause Lynch syndrome, also known as 
hereditary nonpolyposis colorectal cancer (HNPCC). Lynch syndrome is an 
autosomal dominantly inherited cancer syndrome and is associated with a 
strongly increased risk of developing colorectal and endometrial cancer 
and, to a lesser extent, a range of other tumours including cancer of the 
small bowel, stomach, ovaries, renal pelvis, ureter, brain, and sebaceous 
glands. Lynch syndrome associated tumours are characterized by DNA 
mismatch repair deficiency which can be demonstrated by the presence of 
microsatellite instability in the vast majority of cases. Usually, these tumours 
have physically or functionally lost the wild type MMR allele of the gene 
mutated in the germline, which can be demonstrated as absence of 
immunohistochemical staining of the MMR protein in question [1]. The 
detection of truncating MMR gene mutations in patients suspected of 
having Lynch syndrome generally offers a good clinical handle for diagnosis 
and genetic counselling and allows for pre-symptomatic testing in relatives. 
In contrast, the clinical implications of most missense mutations and small 
in-frame deletions are unclear (unclassified variants, UVs). A significant 
proportion of DNA variations found in Lynch syndrome (suspected) patients 
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are such UVs: 32%, 18%, 38% and 87% for MLH1, MSH2, MSH6 and 
MLH3, respectively [2]. Investigators and the clinicians confronted with 
these UVs would be assisted by online resources that store information on 
these types of variants. MMR variant databases already exist and the MMR 
Genes Variant Database (www.med.mun.ca/MMRvariants ), the InSiGHT 
mutation database (www.insight-group.org) and the Human Gene Mutation 
Database (www.hgmd.org) are probably the most widely consulted for 
these genes. Their developers and curators do an impressive job of 
cataloguing published as well as, depending on the database in question, 
unpublished MMR gene variants. However, these databases do not report 
in great detail the functional aspects and other findings that may help in 
clinically classifying these MMR variants. Therefore, we set out to build an 





We searched the English literature through Entrez PubMed 
(www.ncbi.nlm.nih.gov/sites/entrez) using sets of keywords to identify 
publications on the functional analysis of human mismatch repair gene 
mutations and selected for missense mutations and small in-frame 
deletions. The reference lists of publications found through this approach 
were searched for additional relevant papers. Details presented in the 
selected papers were collected on the type of mutation, the observed 
clinical phenotype, family history, results of tumour analysis with respect to 
MSI testing and immunohistochemical staining for the MMR proteins, 
frequency of the variants detected in controls, segregation of the mutation 
within the family, evolutionary conservation, type of functional assays used 
and outcome of the analysis using those assays. Only those mutations with 
reported results of functional testing were subsequently included in the 
database. Variant nomenclature was used as proposed by the Human 
Variome Project (report by Dr.J.den.Dunnen, available at 
www.hgvs.org/mutnomen). Reference sequences used were as listed in 
Genbank (www.ncbi.nlm.nih.gov/Genbank) entries NM_000249 for MLH1, 
NM_000251 for MSH2, NM_000179 for MSH2 and NM_000535 for MSH6, 
respectively. Depending on the information available, each of the variants 
was labelled with a certain degree of pathogenicity, ranging from non- 
pathogenic to pathogenic. This labelling was given for research purposes 
only at this stage, using our expert opinion rather than any formal algorithm. 
The data thus collected were stored first in an offline Microsoft Access ( 
Microsoft Corp., Richmond, USA) relational database and subsequently 
ported to a Microsoft SQL Server ( Microsoft Corp., Richmond, USA) 
online environment. Interfaces for data retrieval by external users and for 
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editing the database were programmed using ASP.NET Access ( 





At the time of submission the database contained information on 69 
variants for MLH1, 35 for MSH2, 8 for MSH6 and 3 for PMS2. The 
functional studies and their outcome published for these mutations have 
recently been reviewed in detail elsewhere [3]. Based on the functional 
data, more than half of these UVs probably is pathogenic, underlining the 
clinical importance of studying these UVs.  
The database can be searched at www.mmrmissense.org through a user 
interface as shown in figure 1. The results and print lay-out can be sorted in 
many ways by simply clicking on the column headers. The number of 
functional tests and clinical reports are shown for each of the individual 
variants. Details can be displayed by clicking on the “Show Details” button 
(example shown in figure 2). New data can be added to the database by 
the curators through a range of editing tools, but also by external users 
(after a check by the curators) through a special online form. 
 
 



























We have constructed an online database for information on functional 
assays and other findings that may help in classifying missense variants 
and small in-frame deletions of the Lynch-syndrome associated MMR 
genes. It is important that the pathogenicity of these variants is understood 
for the purpose of genetic counseling and medical management of the 
families in which these variants have been detected. Classifying these 
variants is notoriously difficult. Functional assays may produce 
contradictory results; segregation may not easily be studied due to lack of 
DNA from affected relatives in Lynch syndrome suspected families; number 
of control chromosomes analyzed in regionally/ethnically matching 
populations may be small; and reported clinical and tumour phenotypes 
may lack detail. For many MMR gene UVs data are incomplete as was 
recently shown by Lucci-Cordisco et al. [4].   
 
Before evidence can be weighed and variants classified, data should be 
available for that purpose and many challenges from the point of 
databasing exist in this respect. Keeping up to date with published reports 
requires effective and efficient literature mining techniques. For this 
purpose, we are in contact with researchers from the department of 
Computer Science and Software Engineering at the National ICT Australia 
Victoria Research Laboratory of the University of Melbourne who may be 
able to improve our methods of mining relevant literature. Getting 
unpublished data in a central database is another challenge. Several 
incentives should be developed to stimulate local laboratories or national 
laboratory professional societies to submit their data to international online 
databases, for example inclusion as electronic publication in PubMed for 
mutations submitted to databases. National, regional or local legislation and 
rules with respect to privacy and medical confidentiality may prohibit 
clinicians and DNA laboratories from submitting detailed phenotypic 
information on their patients and their families with UVs or other types of 
mutations. Another issue is interpreting the co-occurrence of multiple MMR 
gene UVs in individual patients. We and others have observed several of 
these co-occurrences of missense mutations in series of patients tested 
because of suspected Lynch syndrome. Most information in databases is 
listed for single variants and adjustments should be made to allow 
information storage and retrieval for combinations of these variants. 
Needless to say, functional analysis of these combinations of variants is a 
challenge in itself.  
 
Methods are needed to weigh available evidence in a structured way. One 
step in this process would be comparative analysis of the available 
evidence. For example, computational methods based on comparative 
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sequence and or protein structure to classify UVs are not necessarily in 
agreement. Several studies have demonstrated that in silico predictions of 
MLH1 and MSH2 splicing defects can be unreliable and should be 
complemented by in vivo studies (which may even reveal tissue-dependent 
splicing) whenever possible[5,6]. If the in silico predictions are concordant, 
however, then predictive value is much improved, as has been recently 
been demonstrated by Chan et al. who compared the outcome of these 
type of computational methods with the outcome of functional analysis for 
MLH1 and MSH2 [7].  
 
For BRCA1 and 2 variants, Easton et al. recently compared personal and 
family history of cancer, segregation of the variant in families and co-
occurrence with known deleterious mutations, with position of the mutation 
in functional domains, evolutionary conservation and predicted splice site 
involvement. Variants predicted to be pathogenic based on the clinical data 
also were likely to have high conservation, more likely to affect splicing and 
to be located in particular protein domains. [8]. In another comparative 
study on BRCA1 mutations, Lovelock et al. compared the results from a 
multifactorial likelihood analysis incorporating evolutionary conservation, 
segregation in families, co-occurrence with known pathogenic mutations 
and histopathology with the outcome of functional analysis. This likelihood 
analysis was shown to improve classification of some variants, whereas 
conflicting results from functional analysis were present in others. [9]. 
Approaches like these may prove of value in the classification of MMR 
gene variants. They may for example help in testing and further developing 
scoring systems like that of Barnetson et al. who recently published a 
system to classify MLH1, MSH2 and MSH6 UVs [10]. These authors noted 
lack and contradictory results of functional data and discordant in silico 
predictions of effects on splicing and protein function of UVs that had been 
detected in a large series of colorectal cancer patients. Most weight in their 
scoring system is attributed to absence of the UVs in controls, segregation 
in family members, loss of expression of the relevant MMR gene and 
presence of tumour microsatellite instability in the tumour. Ideally, 
unclassified MMR gene variants mutations should be clinically classified by 
a broad expert panel. Such a panel and professional organization behind it 
might also carry more weight in directing additional research to fill in the 
data that are needed to classify particular mutations and possibly apply for 
funding that is needed to support that research. 
 
Lynch syndrome is not a rare disorder and with the increasing availability of 
mutation analysis a substantial contribution to the already known pool of 
unclassified MMR gene variants can surely be expected. The need for 
clinical classification of these variants will increase likewise. Within the 
community of the International Society for Gastrointestinal Hereditary 
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Tumours (InSiGHT) there is a strong motivation to address these issues. 
InSiGHT activities will include interconnecting or integrating the existing 
MMR gene databases and bringing researchers and clinicians together to 
explore the possibility of building an expert panel for MMR gene variant 
classification. These joint activities and their outcome may help those 
interested in other disorders and genes to develop their own strategies of 
addressing the problem of unclassified gene variants. 
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Background: So far 18 MLH3 germline mutations/variations have been 
identified in familial colorectal cancer cases. Sixteen of these variants are 
amino acid substitutions of which the pathogenic nature is still unclear. 
These substitutions are known as unclassified variants or UVs.  
Aim: To clarify a possible role for eight of these MLH3 UVs identified in 
suspected Lynch syndrome patients, we performed functional tests. 
Methods and results: Of eight UV-containing MLH3 mutants we 
determined the protein expression and stability, protein localisation and 
interaction of the mutant MLH3 proteins with MLH1. All eight MLH3 UVs 
gave protein expression levels comparable with wildtype MLH3. 
Furthermore, the UV-containing proteins were all localised normally in the 
nucleus and they interacted normally with wildtype MLH1.  
Conclusion: Our different functional assays yielded no evidence that the 
eight MLH3 UVs tested are the cause of hereditary colorectal cancer, 





Mismatch repair (MMR) proteins form a highly conserved group of proteins 
that play a crucial role in correcting DNA mismatches that have escaped 
the proofreading activity of DNA polymerases. In the human MMR system 
the mismatch recognition component is fulfilled by a heterodimeric protein 
complex composed of two MutS homologous (MSH) proteins. The major 
MSH-heterodimer consists of MSH2 and MSH6 (MUTSα). This heterodimer 
is able to recognise and bind to base-base mismatches as well as to small 
insertion/deletion loops. A minor and partially redundant mismatch 
recognizing/binding heterodimer called MUTSβ consists of the MSH2 and 
MSH3 proteins. This protein complex recognises and binds mainly to larger 
insertion/deletion loops (1). During the mismatch repair process, when 
MUTSα/MUTSβ recognise DNA mismatches that arise during DNA 
replication, the protein complex binds to the mismatch, thereby inducing a 
conformational change of the heterodimer and allowing ATP to bind and 
activate the protein complex. After activation of the MUTS complex, a 
heterodimer of two MutL homologous (MLH) proteins will bind to the 
DNA/protein complex. Two heterodimers composed of either MLH1 or 
PMS2 (MUTLα) or MLH1 and MLH3 (MUTLγ) are proven interactors with 
the MSH2-containing DNA-protein complex. These MLH complexes are 
thought to coordinate the downstream repair events, involving different 
proteins such as exonucleases (e.g. EXO1) and DNA polymerases (2-4). 
The heterodimer MLH1-PMS2 (MUTLα) interacts with both MUTSα and 
MUTSβ, while the heterodimer MLH1-MLH3 (MUTLγ), appears to interact 
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with only MSH2-MSH3. In particular, the role of MLH3 in MMR has been 
under debate as no MMR involvement could be shown in yeast (5). Chen 
and co-workers (6), however, showed in mice that Mlh3 deficiency causes 
microsatellite instability, impaired DNA damage response and increased 
gastrointestinal tumour susceptibility. Furthermore, cultured mammalian 
cells, stably expressing a dominant negative truncated human MLH3, 
showed microsatellite instability (MSI) (7). For an excellent review on the 
MMR process in humans see (8). 
Loss of MMR proteins results in the accumulation of unrepaired mutations. 
It is therefore not unexpected that mutations in these MMR genes are 
associated with tumour development. Germline mutations in four MMR 
genes, namely MLH1, MSH2, PMS2, and MSH6, have been identified in 
the majority of families with hereditary nonpolyposis colorectal cancer or 
Lynch syndrome (9). Many of the mutations identified result in premature 
termination of translation and thus in loss-of-function of the encoded 
mutated protein. This loss of MMR function results in unrepaired mutations 
in non-coding but also in coding sequences. It is mainly these coding 
sequence mutations that contribute to tumour development (10). 
Recently, we identified nine MLH3 missense mutations and a MLH3 
frameshift mutation in patients suspected of having Lynch syndrome (11). 
The missense mutations will be called UVs throughout this paper since it is 
not yet known whether these DNA variants contribute to disease 
development. Identifying these DNA variants, in combination with the 
identification of somatic MLH3 mutations in three tumours of patients with 
these DNA variants (11), led us to hypothesise that, besides the four known 
MMR genes, MLH3 might also play a role in Lynch syndrome development. 
However, as all but one of the variations identified so far were UVs, the role 
of MLH3 in the development of Lynch syndrome is still under debate. We 
functionally tested eight identified MLH3 UVs to see whether there is a 
possible role for MLH3 in Lynch syndrome. 
 
 
Material and methods 
 
Cell lines 
HEK293T cells, human embryonic kidney cells that lack MLH1 and MLH3 
expression due to hypermethylation of the promoter regions of both genes 
(12), were grown in DMEM, supplemented with 10% foetal bovine serum, 
1% penicillin-streptomycin and L-Glutamine (all from Invitrogen, Breda, the 
Netherlands). HeLa cells (ATCC CCL-2) were grown in DMEM containing 





In silico analysis of the unclassified variants in MLH3 
A description of the different MLH3 UVs that were tested and the clinical 
characteristics of the mutation carriers are given in Table 1 and in Figure 1. 
Alignments with MLH3 homologous from six other vertebrates were 
obtained by blasting the complete MLH3 protein. The program used was T-
Coffee (http://www.tcoffee.org) (13). The following seven sequences were 
used in the Blast search: Homo sapiens, Rattus norvegicus, Mus musculus, 
Canis familiaris, Bos taurus, Gallus gallus, and Xenopus tropicalis. 
 All eight MLH3 UVs were further analysed in silico for putative 
functional effects using the polymorphism phenotyping (PolyPhen) 
algorithm (http://genetics.bwh.harvard.edu/pph). PolyPhen is a web-based 
algorithm that predicts how an amino acid substitution could possibly affect 
the structure and function of a human protein using straightforward physical 
and comparative considerations. Calculations are based on amino acid 
homology. In silico analysis using the PolyPhen algorithm was done on the 
entire MLH3 protein sequence (including the UVs). Amino acid substitutions 
are reported as benign, possibly damaging or probably damaging. 
Three web-based algorithms were used to predict possible splice defects 
initiated by the UVs: Netgene2 (http://www.cbs.dtu.dk/services/NetGene2), 
Splicesitefinder (http://violin.genet.sickkids.on.ca/~ali/splicesitefinder.html), 
and Splicesite predict (http://www.fruitfly.org/seq_tools/splice.html). As input 
we gave a fragment containing the exon sequence plus 200 nucleotides 
upstream and 200 base pairs downstream of the exon. This was done for 




Table 1. Genetic and clinical data of the tested MLH3 UVs.  
 
* loss of MSH6 is due to the truncating mutation identified; none of the families fulfilled the 
Amsterdam II criteria; CRC=colon cancer, EC=endometrial cancer, OV=ovarian cancer; 
H=MSI-H, L=MSI-L, ND not determined.  
 
We also ran ESEfinder (http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi? process=home), a program that searches for 
sequences that act as binding sites for four members of the serine/arginine 
rich family of splicing enhancer proteins. Input sequences are screened for 
consensus binding sequences for the SR proteins CF2/ASF, SC35, SRp40 
and SRp55. Regions with scores above a certain threshold value are 
predicted to act as SR protein binding sites and thus function as ESEs 
(exonic splice enhancers). The wildtype (or UV-containing) MLH3 cDNA 
sequence (AB 039667) was used as input. The program was run in an 
exon-by-exon manner. 
 
MLH3 vectors and MLH3 mutants 
To clone the MLH3 cDNA (wildtype) in pAS2 (a yeast two-hybrid vector 
containing a GAL4 DNA binding domain) and pACT2 (a yeast two-hybrid 
vector containing a GAL4 activation domain), MLH3 was first cloned into 














1 c.70C>G p.Gln24Glu  CRC 50 H +/+/+ 
1 c.1496A>G p.Asn499Ser  CRC 62 
EC 63 
H +/+/+ 
1 c.1870G>C p.Glu624Gln  CRC 20 ND +/+/+ 








1 c.2533A>G p.Ser845Gly  EC  L ND 
1 c.2578delA p.N860IfsX13  CRC 43 L +/+/+ 
1 c.2941G>A p.Gly981Ser  CRC 24 L +/+/+ 
1 c.3020A>G p.Asn1007Ser  CRC 49 L +/+/+ 











CRC41 ND +/+/-* 
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pBluescript (a generous gift from Dr. Steven Lipkin, Departments of 
Biological Chemistry and Medicine, University of California, Irvine, USA). 
MLH3 was PCR-amplified using primers containing the 5’ end and the 3’ 
end of the coding sequence coupled to a BamHI (forward) and an Eco47III 
(reverse) restriction site. An extra AG was inserted between the BamHI site 
and the first codon of MLH3 (to get MLH3 in the correct reading frame after 
subsequent subcloning into pACT2 and pAS2). After cloning this PCR-
amplified MLH3 in pBluescript, the insert was sequenced and subcloned in 
pACT2 and pAS2 using the BamHI and Eco47III restriction sites. Mutations 
(i.e. the eight UVs mentioned in Table 1, one known polymorphic missense 
variant (p.Ser845Gly) and the identified frameshift mutation (see Table 1)) 
were introduced in these plasmids using the Stratagene QuickChange XL 
Mutagenesis Kit (La Jolla, CA, USA). This was done according to the 
manufacturer’s instructions. After mutagenesis the MLH3 inserts were 
sequenced to confirm the mutation status of the plasmids.  
Wildtype MLH3 (out of pBluescript) was cloned directly, in-frame with YFP, 
into pEYFPC1 (Clontech Laboratories, Woerden, the Netherlands) and the 
constructed YFP-MLH3 vector was used for subcellular localisation studies. 
Mutations (i.e. the eight UVs mentioned in Table 1, one known polymorphic 
missense variant (p.Ser845Gly) and the truncating mutation we identified 
(see Table 1)) were introduced in WT-YFP-MLH3 using the Stratagene 
QuickChange XL Mutagenesis Kit (La Jolla, CA, USA). This was done 
according to the manufacturer‘s instructions. After mutagenesis all inserts 
were verified by sequencing.  
 
Protein expression of MLH3 in the HEK293T cell line 
HEK293T cells were seeded in a 6-well plate 24 hours before transfection 
to ensure 60% confluence on the day of transfection. 4 µg of YFP-MLH3 
vector (WT or mutant) was transfected using 10 µl lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA). WT-CFP-MLH1 and WT-YFP-MLH3 were 
used as positive controls. Transfected HEK293T cells were lysed 48 hours 
after transfection using a non-denaturing lysis buffer (20mM Tris-HCl, pH 8, 
135 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 
protease inhibitors). Protein concentration determinations were performed 
according to Bradford (14). 75 µg of the cell lysate was loaded and size 
separated on a 6% SDS-PAGE gel. After separation by SDS-PAGE, 
proteins were transferred to a nitrocellulose membrane (Bio-Rad, 
Veenendaal, the Netherlands). MLH3 was detected with specific antibodies 
(Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) or with anti-GFP 
(GeneTex, Inc, San Antonio, TX, USA) and anti-mouse IgG HRP-
conjugated secondary antibody (Pierce Biotechnology, Rockford, USA). 
Beta-tubulin (a housekeeping protein) was used as an internal loading 
control and detected with an anti-beta-tubulin antibody (Sigma-Aldrich 
Corp, St. Louis, MO, USA) and anti-mouse IgG HRP-conjugated secondary 
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antibody (Pierce Biotechnology, Rockford, USA). Signal visualisation was 
performed with the Supersignal West Dura Extended Duration Substrate kit 
(Pierce Biotechnology, Rockford, USA). 
  
Subcellular localisation of MLH3 
On the day prior to transfection, 100.000 cells were seeded in small glass 
petri dishes (20 mm in diameter). On the day of transfection, the media 
were refreshed. For transfection 1 µg of plasmid DNA (also 1 µg in total for 
the double transfection experiments) and 3 µl Fugene6 per petri dish was 
used. Fugene6 (3 µl) was mixed with 50 µl optimem and incubated for 5 
minutes at room temperature. DNA was added and mixed, and this mixture 
was incubated for 20 minutes after which it was added to the cells. The 
cells were then incubated for ~24 hours. After incubation, the transiently 
expressed, fluorescently labelled proteins were visualised by confocal laser 
scanning microscopy (Zeiss LSM510, Carl Zeiss MicroImaging GmbH, 
Jena, Germany). 
 
Yeast two hybrid analysis 
To investigate the ability of UV-containing MLH3 proteins to form MLH1-
MLH3 heterodimers, yeast two-hybrid assays were performed essentially 
as described by Rasmussen et al. (15). pAS2-MLH1 and pACT2-MLH3 
were co-transformed into the Saccharomyces cerevisiae strain Y190. 
Transformants were selected on synthetic dextrose minimal medium (SD) 
lacking tryptophan, leucine and histine (SD/-Trp/-Leu/-His). At least five 
colonies were streaked onto an SD/-Trp/-Leu/-His plate that was 
supplemented with 25 mM 3-amino-1,2,4-triazole(3-AT). Colonies were 
further tested on SD/-Trp/-Leu/-His/3-AT + 40 µg/ml 5-bromo-4-chloro-3-
indolyl-ß-D-galactosidase (X-gal) plates. Blue colonies that can grow on 
these selection plates express GAL4-tagged proteins that are able to 
interact. The two-hybrid vectors containing MLH3 or MLH1, in combination 





In silico analysis of the unclassified variants in MLH3 
The results of the in silico analyses of the MLH3 UVs are presented in 
Table 2 and Figure 2. Seven of the eight UVs were predicted to be benign 
based on PolyPhen, a program partially based on conservation. Only the 
mutation p.Asn499Ser was predicted to be possibly pathogenic based on 
the PolyPhen algorithm.  
A study for the possible splicing effects of the UVs, as determined 
by Netgene2, Splicesitefinder, Splice Site Predict and ESEfinder, made 
clear that none of the UVs were likely to cause splice defects. This analysis 
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included donor and acceptor site changes as well as inactivation of exonic 
splicing enhancer sequences.  
 
Table 2. In silico analyses of the eight tested MLH3 UVs.  
 







p.Gln24Glu (p.Q24E) P→AP benign no 
p.Asn499Ser (p.N499S) P→P possibly 
pathogenic 
no 
p.Glu624Asp (p.E624D) AP→AP benign no 
p.Ser817Gly (p.S817G) P→NP benign no 
p.Gly981Ser (p.G981S) NP→P benign no 
p.Asn1007Ser (p.N1007S) P→P benign no 
p.Ala1394Thr (p.A1394T) NP→P benign no 
p.Glu1451Lys (p.E1451K) AP→BP benign no 
P=polar amino acid (AA), NP=non-polar AA, AP= acidic charged polar AA, BP= basic 
charged polar AA. 
 
 The alignment depicted in Figure 2 shows that three of the eight 
UVs changed highly conserved amino acids (p.Gln24Glu, p.Glu624Asp, 
and p.Ala1394Thr), whereas two of the eight UVs changed reasonably well 
conserved amino acids (p.Asn1007Ala and p.Glu1451Lys). 
 These in silico experiments suggest that the MLH3 UVs are likely to 




































Figure 1. Schematic representation of the MLH3 protein and location of the tested MLH3 
UVs and the truncating mutation in the protein. The light blue parts of the protein represent 






















Figure 2. Alignment of the human MLH3 protein with MLH3 proteins of different vertebrates. 
The alignment includes the (putative) MLH3 proteins of the following organism: Homo 
sapiens, Bos taurus, Canis familiaris, Gallus gallus, Mus musculus, Rattus norvegicus, and 
Xenopus tropicalis. Only protein regions that contain the tested UVs are presented in this 
figure. Identical amino acids (*), conserved substitutions (:), or semi-conserved substitutions 






















Transient expression of MLH3 in HEK293T cells 
To evaluate the stability of the WT- or Mutant-YFP-MLH3 proteins, we 
transiently expressed Mutant-YFP-MLH3 in HEK293T cells. Notably, 
HEK293-T cells are deficient for both MLH1 and MLH3 due to 
hypermethylation of the promoter regions of both genes (12). The wildtype 
MLH3 protein was stably expressed, even in the absence of MLH1 (see 
Figure 3) and the MLH3 expression levels of all UV-containing proteins 
were comparable with the expression level of the WT-YFP-MLH3 (see 
Figure 3A) and that of one known missense polymorphism (p.Ser845Gly). 
The MLH3 protein variant with a frameshift mutation, p.Ans860IfsX13, was 
not detectable (see Figure 3A). This was caused by shortening of the 
protein leading to a loss of the epitope recognised by the MLH3-antibody. 
The MLH3 (H-2) antibody is a mouse monoclonal antibody raised against 
amino acids 1228-1453 of human MLH3. To verify the presence of the 
truncated protein, we reprobed the blot with an anti-GFP antibody. A protein 
with the size expected for the truncated protein was detected (around 126 
kD), see Figure 3B. These results suggest normal expression of all UV-
containing MLH3 proteins. 
 
Subcellular localisation of MLH3 
In order to evaluate whether the UV-containing MLH3 proteins were 
transported correctly into the nucleus, WT-YFP-MLH3 and Mutant-YFP-
MLH3 were transfected into HEK293T cells or into HeLa cells. Figure 4 
shows representative results of these experiments in HeLa cells (similar 
results were obtained in HEK293T cells, data not shown). In the HeLa and 
HEK293T cell lines, being MLH3-deficient and -proficient, respectively, all 
mutated and WT proteins were mainly localised in the nucleus. Some 
cytoplasmatic staining was seen, although this was independent of the 
presence of MLH1. These results suggest that the subcellular localisation of 
the mutated proteins is normal. The subcellular localisation for the MLH3 
protein containing a truncating mutation clearly differs from the UV-
containing mutations since, besides the nuclear staining, a strong 











Figure 3.  A. Expression of (UV-containing) MLH3 in HEK293T cells. This Western blot, 
using an MLH3 specific antibody, shows no differences in MLH3 expression when 
comparing cells transfected with WT-MLH3 and those transfected with UV-containing MLH3.  
B. Expression of MLH3 in HEK293T cells. This Western blot, using a GFP antibody shows in 
all but one lane the expected band of 190 kD. In lane 7 (extracts from cells transfected with 
p.Asn860lfsX13-MLH3) a lower band is visible (126 kD). Data shown are representative of 
three independent experiments. In this figure, in all lanes an aspecific band of approximately 
150 kD is visible. 
 
 
Yeast two-hybrid analysis 
To determine whether MLH1 and UV-containing or wildtype MLH3 are able 
to form protein dimers in vivo, we performed a yeast two-hybrid screen. The 
screen, as shown in Figure 5, showed the eight MLH3 UVs analysed, one 
known MLH3 missense polymorphism (p.Ser845Gly), and the MLH3 
frameshift mutation identified (see Table 1). All mutated MLH3 proteins 
were able to interact with WT-MLH1 and this interaction was comparable 
with WT-MLH3-WT-MLH1 interaction and with that of the known missense 
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polymorphism. The data suggest that the UV-containing MLH3 proteins can 
bind to WT-MLH1 in vivo.  
The control experiments also showed colonies for the combination of the 
two empty vectors and the combination of pAS2 (empty vector) with 
pACT2-MLH3. The observed colonies, however, were white whereas the 
colonies observed for the WT-MLH1 with WT- or MUTANT-MLH3 were all 
blue, as expected. We also observed interaction between the truncating 
MLH3 mutation (p.Ans860IfsX13) and WT-MLH1. Unexpectedly, no 
colonies were seen when testing the interaction between p.MLH1 and 
p.Glu1415Lys. This could point towards a loss of interaction, but as we did 






Protein expression/stability studies 
Transfection of mutant and WT-MLH3 in an MLH3-deficient cell line, 
HEK293-T, showed no difference in protein levels for the UVs tested. Our 
data also showed that the MLH3 protein is stable without a heterodimeric or 
other partner, corroborating previous findings (12). 
 
MLH3 localisation studies  
To repair mismatches in vivo, the MLH3 protein needs to be present in the 
nucleus. Recent localisation experiments (17) suggested that endogenous 
MLH3 is mainly localised in the cytoplasm whereas MLH1 and PMS2 are 
localised in the nucleus in a human MMR-proficient cell line. It was also 
shown that when MLH3 was transiently expressed in HCT116 (a human cell 
line deficient for MLH1 and PMS2), the MLH3 protein also localised in the 
cytoplasm. Only after co-transfection with MLH1, Sunyaev et al. (18) saw 
that MLH3 was partially transported into the nucleus. Furthermore, co-
transfection of MLH3 with both MLH1 and PMS2 resulted in a cytoplasmatic 
localisation of MLH3, suggesting that MLH3 localisation not only depends 
on MLH1 but is also in competition with PMS2 (18). Our data do not 
corroborate these findings as we observed that both WT and UV-containing 
MLH3 proteins were largely located in the nucleus and only partially in the 
cytoplasm, regardless of whether MLH3 was transfected alone or co-
transfected with MLH1 and regardless of the cell line we used for 
transfection. These results suggest, in contrast to Sunyaev et al.’s study, 
that nuclear MLH3 localisation does not depend on MLH1. When 
transfecting the vector expressing the truncated MLH3 protein 
(p.Asn860IfsX13) however, more cytoplasmatic staining can clearly be seen 
(see Figure 4). The protein, however, is normally not expressed as the 
naturally occurring unprocessed mRNA containing such a frameshift 
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Figure 4. Subcellular localisation of CFP-MLH1 and YFP-MLH3, WT-MLH3, nine UV-




































Figure 5. ß-gal assays (yeast two-hybrid 
assays) for WT-MLH3, nine UV-
containing MLH3s, and one truncating 
mutation containing MLH3. Panels 1-11 
show the interaction between MLH3 (with 
the indicated UV) with WT-MLH1. Panel 
12. WT-MLH1 combined with empty 
vector, Panel 13. MLH1 (with a truncating 
mutation) combined with WT-MLH3, 
Panel 14. WT-MLH3 combined with an 
empty vector, Panel 15. two empty 
vectors, Panel 31. MLH3 coupled to the 
GAL4 activation domain instead of the 
GAL4 DNA binding domain (as is used in 
all other experiments) combined with 
empty vector. 
WT-MLH3 p.Gln24Glu p.Asn499Ser p.Glu624Gln
p.Ser817Gly p.Ser845Gly p.N860IfsX13 p.Gly981Ser
p.Asn1007Ser p.Ala1394Thr p.Glu1451Lys
MLH1-empt vec MLH3-MLH1 trunc MLH3-empt vec Empty vectors
p.N860IfsX13-empt vec
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Yeast two-hybrid studies 
To study whether the identified MLH3 UVs influence the interaction with 
MLH1 in vivo, we tested the ten MLH3 mutants in a yeast two-hybrid 
system. Yeast two-hybrid studies showed that all the analysed MLH3 
mutants were able to interact with WT-MLH1 and that these interactions 
were comparable with a WT-MLH3-WT-MLH1 interaction. The 
p.Glu1451Lys MLH3 protein was an exception as we did not obtain any 
colonies at all, but since we also saw no normal colonies on a minimal 
selection medium, we assume that the lack of colonies is due to a failed 
experiment rather than a lack of interaction. 
Surprisingly, we also observed interaction between the truncating MLH3 
mutation (p.Asn860IfsX13) and WT-MLH1. A plausible explanation for this 
would be that a truncated MLH3 protein is produced, as shown in Figure 3B 
(see Results section, protein expression/stability studies). This truncated 
protein might still be able to interact with MLH1 to form a heterodimer with 
MLH1. Notably, the N-terminal MLH1 interaction domain was still present in 
the truncated form of MLH3, whereas the entire C-terminal MLH1 
interaction domain was lacking (Figure 1). 
 
In conclusion, these functional assays do not show a change in the function 
of the mutated proteins we tested. Not finding a functional defect in these 
assays does, however, not preclude the MLH3 UVs being involved in Lynch 
syndrome. The assays described above investigate only specific aspects of 
MMR protein functioning. It is conceivable that the UVs tested can cause a 
functional defect of the protein that was not detectable with the assays 
used in this study. We cannot therefore fully exclude these UVs from being 
pathogenic. 
 
Theoretical arguments for pathogenicity of MLH3 UVs 
Besides data from functional assays, we also collected theoretical 
arguments that might help in determining the pathogenic nature of the 
MLH3 amino acid substitutions identified. We determined conservation in 
six vertebrates and showed that two of the amino acids that were mutated 
are highly conserved (Figure 2). We also looked for polarity changes and 
saw again that several of the UVs give rise to substantial changes in 
polarity. However, when all these data were combined in a program called 
PolyPhen we saw that only one of the eight UVs could be considered as 
possibly causative. The PolyPhen software combines structural, 
evolutionary and physicochemical properties. Notably, validation of the 
program showed a proper prediction in only 80% of known deleterious 
mutations, and thus false-positive or -negative findings can be expected 
(18,19), However, the prediction results are in line with the functional 
assays described above, with the exception of p.Asn499Ser, which was 
predicted to be possibly pathogenic. Our in silico analysis on splicing 
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showed that splicing abnormalities were not predicted for any of the UVs.  
Based on the results from the functional assays and the theoretical 
prediction algorithms, we conclude that we have no convincing evidence 
that the MLH3 UVs tested are involved in the development of Lynch 
syndrome. 
 
Is MLH3 involved in Lynch syndrome? 
This leaves us with the question whether mutations in MLH3 can contribute 
to the development of Lynch syndrome? Our data do not support any 
involvement of the MLH3 UVs identified in Lynch syndrome. Whether or not 
this can be concluded for the two reported MLH3 frameshift mutations 
(11,16) remains unanswered. The fact that the tumours of these patients 
were MSI-low might be an argument against involvement in 
tumourigenesis. On the other hand, the finding of somatic mutations, 
knocking out the second allele in the tumour in three of the nine patients, 
argues in favour of their involvement (11). Finding MSI-L tumours in these 
patients should also be no surprise since it was shown that only a small but 
significant (20%) repair of both G/T mismatches and +1 insertion/deletion 
loop substrates was observed when MMR-deficient HEK293T nuclear 
protein extracts were supplemented with high amounts of MUTLγ. This 
suggests that MUTLγ might play a backup role in human MMR (12). A low 
activity is also reflected in the presence of low amounts of endogenous 
MLH3 protein in human cell lines. Semi-quantitative Western analysis of 
HeLa cells revealed endogenous MLH3 levels 60 times less abundant than 
in PMS2 and 6 times less abundant than in PMS1 (12). 
 
Conclusion 
We analysed the functional significance of eight MLH3 UVs that had not 
previously been evaluated in functional assays. Our assays show that the 
MLH3 UVs are likely to be as functional as the wildtype MLH3 protein, 
suggesting that MLH3 is not a major player in Lynch syndrome. However, 
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Inherited pathogenic mutations in the mismatch repair (MMR) genes MLH1, 
MSH2, and MSH6 predispose to Lynch syndrome. Major challenges in 
Lynch syndrome diagnostics are the DNA variants with an unclear 
pathogenic nature (unclassified variants, UVs), such as single amino acid 
substitutions and small or large in-frame deletions. In particular MSH6 UVs 
account for a substantial proportion of these UVs. This study has been 
performed to evaluate the pathogenicity of five of such inherited MSH6 UVs 
found in patients suspected of Lynch syndrome. 
Methods 
The mutated MSH6 proteins, all containing single amino acid substitutions, 
were tested for expression and stability in an MSH2/MSH6-deficient cell 
line (LOVO), for interaction with MSH2 by yeast two-hybrid experiments 
and for its subcellular localization. 
Results 
Protein expression of four of the five MSH6 mutants (p.Ser144Ile, 
p.Ala1021Asp, p.Ala326Val, and p.Thr1219Ile) was significantly decreased 
after transfection when compared with the expression of wildtype MSH6. 
Determining MSH6 gene expression by real time PCR showed a high 
similarity between the protein and the gene expression patterns. This 
suggests that the low protein expression is caused by low mRNA levels. No 
effects were observed on protein-protein interactions and the subcellular 
localization for all five MSH6 UVs was comparable to that of the WT MSH6.  
Conclusion 
Our data show that four of the five tested MSH6 UV seem to have an 
influence on gene expression and thereby on protein translation. Why the 
expression of these four UV-containing proteins in vivo is reduced is yet 





Lynch syndrome or Hereditary Non-Polyposis Colorectal Cancer (HNPCC) 
is the most common autosomal dominant inherited colorectal cancer 
syndrome known. Lynch syndrome is caused by germline mutations in DNA 
mismatch repair (MMR) genes of which the majority are found in MSH2 and 
MLH1 (1). Additionally, five to ten percent of Lynch syndrome families carry 
a germline mutation in the MSH6 gene (2;3), but the number of mutations 
reported in the MSH6 gene is continuously rising. Besides a lower 
frequency of mutations in the Amsterdam criteria positive families, the 
average age of onset compared to MSH2 and MLH1 mutation carriers is 
higher in MSH6 mutation carriers (4) and therefore germline mutations in 
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the MSH6 gene are recognized more frequently in so-called atypical Lynch 
syndrome or late onset families, families that do not fulfil all the clinical 
“Amsterdam criteria“ (2). Furthermore, in families having germline MSH6 
mutations endometrial cancer is more frequent (5).   
The involvement of MMR genes in Lynch syndrome can be made visible by 
the presence of small insertions or deletions in simple repetitive DNA 
sequences (also called microsatellite instability high or MSI-H) in tumours 
from these patients (6). Almost all tumours of Lynch syndrome patients 
demonstrate MSI. An exception on this can be found among tumours from 
patients with an MSH6 mutation (7).  
The rarity of MSH6 germline mutations in Lynch syndrome and the atypical 
phenotype conferred by the MSH6 germline mutation can partly be 
explained by redundancy of its function by another MMR protein. MSH6 
forms a protein complex with MSH2, called MUTSα. This protein complex 
recognizes base-base mismatches and insertion/deletion loops and binds 
to these. The function of a second complex consisting of MSH2 and MSH3 
(called MUTSβ) is partly redundant (8). These data are corroborated by 
studies on Msh6-/- mice, which have a reduced lifespan and developed a 
spectrum of tumours, all showing little or no MSI (9). Cellular extracts from 
Msh6-/- cells were deficient for the repair of single nucleotide mismatches 
(10). These findings indicated that inactivation of MSH6 can lead to cancer 
susceptibility and may be associated with cancer predisposition syndrome 
without showing microsatellite instability. 
 
To date, the International society of Gastrointestinal Hereditary Tumours 
(InSiGHT) reports on over forty potentially pathogenic MSH6 mutations in 
their database (http://www.insight-group.org). More than one third of them 
result in an amino acid substitution of which the pathogenic nature is 
unclear. These mutations are therefore called unclassified variants (UVs). 
Only one of them has been proven pathogenic in functional assays (11) 
and few were shown to segregate in families (12). For an overview of 
functionally tested MMR UVs see www.mmrmissense.org (11). To address 
the question of pathogenicity of five of such MSH6 germline UVs, we 
performed several functional assays to determine protein-protein 
interactions, subcellular-localisation and protein expression-protein stability. 
 
 
Material and Methods  
 
Selected UVs  
For this study five UVs were selected. These variants were identified in 
patients with atypical Lynch syndrome. The genetic and clinical 
characteristics of the UVs and the patients carrying the UVs can be found 
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in Table 1. Figure 1 shows a schematic representation of the MSH6 protein 
depicting the functional domains and the position of the UVs in the protein. 
 
 
Table 1. Clinical genetic features associated with five MSH6 missense variants and their 
potential relationship with Lynch syndrome MSH6 UVs.  
Cancer and age of diagnosis: described as tumour type, age of diagnosis. CRC: colorectal 





In silico analysis of the unclassified variants in MSH6 
Alignments with MSH6 homologues from six other vertebrates and yeast 
were obtained by Blasting the complete MSH6 protein. The program used 
was T-Coffee (13) (http://www.tcoffee.org). The following eight sequences 
were used in the Blast search: Homo sapiens; Rattus norvegicus; Mus 
musculus; Canis familiaris; Bos taurus; Gallus gallus; Xenopus tropicalis; 
Saccharomyces cerevisiae. 
All five MSH6 UVs were further analyzed in silico for putative functional 
effects using the Polymorphism Phenotyping (PolyPhen) algorithm 
(http://genetics.bwh.harvard.edu/pph). PolyPhen is a web-based algorithm 
that predicts how an amino acid substitution will possibly affect the 
structure and function of a human protein using straightforward physical 
and comparative considerations. Calculations are based on amino acid 
homology. In silico analysis using the PolyPhen algorithm was done on the 
entire MSH6 protein sequence (including the UVs). Amino acid 
substitutions are reported as benign, possibly damaging or probably 
damaging. 
Three web-based algorithms were used to predict possible splice defects 
initiated by the UVs: Netgene2 (http://www.cbs.dtu.dk/services/NetGene2), 
SpliceSiteFinder (http://violin.genet.sickkids.on.ca/~ali/splicesitefinder.html), 
and Splice Site Predict (http://www.fruitfly.org/seq_tools/splice.html). As 
input we gave a fragment containing the exon sequence plus 200 


















2 c.431G>T p.Ser144Ile EC 45 H +/+/+ - 
2 c.431G>T p.Ser144Ile CRC 48 L +/+/+ - 
2 c.431G>T p.Ser144Ile CRC 49 H +/-/- - 
4 c.977C>T p.Ala326Val CRC 65 H +/+/+ - 
4 c.1565A>G p.Gln522Arg CRC 40 L +/+/+ - 
4 c.3062C>A p.Ala1021Asp CRC 63 L +/+/+ - 
8 c.3656C>T p.Thr1219Ile CRC 37 H +/+/+ - 
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nucleotides upstream and 200 basepairs downstream of the exon. This was 
done for the exons 2, 4 and 8 as all 5 tested UVs are within these exons.  
 
DNA techniques 
MSH6 cDNA (wildtype) was cloned into pFastBac1 (a generous gift from 
Dr. Minna Nystrom-Lathi) between BamHI and XhoI. Using this plasmid, 
wildtype MSH6 was cloned into pCDNA3.1 and pYFPC1. To subclone 
MSH6 WT in pAS2 (a yeast two-hybrid vector containing a GAL4 DNA 
binding domain) and pACT2 (a yeast two-hybrid vector containing a GAL4 
activation domain), we PCR-amplified the gene using pFstBac1-WT-MSH6 
as template using primers containing an additional CG between BamHI and 
the first codon to obtain an in frame GAL4-MSH6 fusion protein.  
pAS2-WT-MSH2 cDNA (cloned within a NcoI site) was used to subclone 
the MSH2-WT in pACT2 (in NcoI) (pAS2-WT-MSH2 was a generous gift 
from Dr. Anna Lutzen, University of Roskilde, Denmark).  
The mutations p.Ser144Ile, pGln.522Arg, p.Ala1021Asp, p.Ala326Val, and 
p.Thr1219Ile were introduced into the MSH6 gene in pFastbac1 and 
pYFPC1-MSH6 using the QuickChange XL mutagenesis kit from 
Stratagene (Stratagene European Headquarters, Amsterdam, the 
Netherlands) following the manufacturers protocols. All mutations were 
confirmed by DNA sequencing (the whole MSH6 insert was sequenced). 
 
The pFastbac1-MSH6 containing the p.Ser144Ile, p.Gln522Arg and 
p.Ala1021Asp were used for subcloning in: pACT2-MSH6 or pAS2-MSH6 
using the restriction enzymes BlnI and BssHII; in pCDNA3.1-MSH6 using 
BamHI and BbvCI for Ser144Ile; in pCDNA3.1-MSH6 using BamHI and 
XhoI for Gln522Arg or Ala1021Asp. The p.Ala326Val and p.Thr1219Val 
mutants were directly introduced in the constructs pAS2-MSH6-WT, 
pACT2-MSH6-WT and pCDNA3.1-MSH6-WT using site-directed 
mutagenesis, followed by direct sequencing to confirm the mutations.  
 
Yeast two-hybrid assay 
The yeast two-hybrid assay was used to assess the interaction between the 
MSH6 (WT and mutant) and WT-MSH2 proteins. In short, pAS2-WT-MSH2 
and pCAT2-WT-MSH6 or PCAT2-mutant-MSH6 were co-transfected into 
the Saccharomyces cerevisiae strain Y190. In the pACT2 vector MSH6 is 
cloned in frame with the activation domain of GAL4 and in pAS2 MSH2 is 
cloned in frame with the GAL4 DNA binding domain. Furthermore, the 
pAS2 vector contains a leucine selection marker and pCAT2 contains a 
tryptophan selection marker. When the proteins are in each others vicinity 
also histidine can be used as a selection marker. Transformants were 
selected on synthetic dextrose minimal medium (SD medium) lacking 
tryptophan, leucine, and histidine. At least five colonies were streaked onto 
SD plates lacking tryptophan, leucine, and histidine and supplemented with 
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25 mM 3-amino-1,2,4-triazole(3-AT)(SD/-Trp-leu-His + 25 mM 3-AT) in 
order to test for protein interaction. Clones capable of growing on SD/-Trp/-
leu/-His + 25 mM 3-AT + 40 µg/ml 5-bromo-4-chloro-3-indolyl-ß-D-
galactosidase (X-gal) should contain proteins that are capable of 
assembling a functional GAL4 transcription factor. These were further 
evaluated for their ß-D-galactosidase activity. MSH6 with a 1201 base 
frameshift deletion was used a negative control. 
 
Cell lines and culturing 
The cell lines used in this study were HeLa and LOVO. The HeLa cell line 
was derived from cervical cancer and the cell line is MMR-proficient. LOVO 
is a human colon adenocarcinoma-derived cell line that is MSH2-deficient. 
The MSH2-deficiency is caused by a homozygous deletion in the MSH2 
gene (exon 3 to exon 8) (14). HeLa cells and LOVO cells were cultured in a 
humidified atmosphere containing 5% carbon dioxide in MEM (Invitrogen, 
Breda, the Netherlands) and RPMI 1640 medium (Invitrogen, Breda, the 
Netherlands), respectively. All media contained 10% fetal calf serum 
(Invitrogen, Breda, the Netherlands). 
 
Transient transfection MSH2 and MSH6 in LOVO  
LOVO cells were grown to 50-80% confluency in a 6 well plate and co-
transfected with 2 µg maxiprep purified pCDNA3.1-MSH2 and 2 µg 
pCDNA3.1-MSH6 (WT or relevant mutants) plasmid DNA that was mixed 
with 5 µl lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Transfections 
were performed according to the manufacturer’s protocol. After 48 hrs the 
cells were harvested and lysed in 20mM Tris-HCl, pH 8, 135 mM NaCl, 1.5 
mM MgCl2, 1 mM EGTA, 1% Triton X-100, 10% glycerol, supplemented 
with protease inhibitor tablets in a 1x final concentration (Roche, Basel, 
Switzerland) for total protein extraction. Protein concentration 
determinations were performed according to Bradford (15). 100 µg total 
protein extract was separated on denaturing 6% SDS polyacrylamide gels 
and blotted onto nitrocellulose membranes (Bio-Rad, Veenendaal, the 
Netherlands). Signal visualization was performed with the Supersignal 
West Dura Extended Duration Substrate kit (Pierce Biotechnology, 
Rockford, USA). The following antibodies were used: anti-MSH2 (Catalog 
No. NA27, Calbiochem, La Jolla, USA; 1:500 dilution), anti-GTBP (MSH6, 
clone 44, Transduction Laboratories, Breda, the Netherlands, 1:250 
dilution) and MLH1 (clone G168-728, Pharmingen, Breda, the Netherlands, 
1:500 dilution) and anti-mouse IgG HRP-conjugated secondary antibody 
(Pierce Biotechnology, Rockford, USA). 
 
Quantitative PCR analysis of MSH6 mRNA  
LOVO cells were grown to 50-80% confluency in 6 well plate and co-
transfected with 2 µg maxi-prep purified pCDNA3.1-MSH2 and 2 µg 
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pCDNA3.1-MSH6 (WT or relevant mutants) plasmid DNA that was mixed 
with 5 µl lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Transfections 
were performed according to the manufacturer’s protocol. 48 hours after 
transfection, total RNA was extracted using RNABee (AMS Biotechnology 
(Europe) Ltd, Abingdon, Oxon, UK).  
First strand cDNA was prepared from 1 µg total cellular RNA using random 
hexadeoxynucleotide primers and first strand cDNA synthesis ready to use 
beads (Amersham, GE Healthcare Europe GmbH, Diegem, Belgium). PCR 
was performed in a volume of 25 µl containing 1X Biorad iQ™ SYBR Green 
supermix (Bio-Rad laboratories B.V, Veenendaal, the Netherlands). SYBR 
Green fluorescence was measured realtime during PCR (IQ 6 PCR, Bio-
Rad Laboratories B.V, Veenendaal, the Netherlands). Quantitative PCR 
was performed in triplicate for MSH2 and MSH6 primer sets and the mean 
value was used as relative quantification value. For normalization the TBP 
gene (TATA box binding protein) was used. 
 
Localization of the MSH6 mutant proteins in the HeLa cell line 
HeLa cells were maintained in DMEM (Invitrogen, Taastrup, Denmark) 
supplemented with 10%FBS (Invitrogen,Taastrup, Denmark) and 1% 
penicillin/streptomycin (Invitrogen, Taastrup, Denmark) and grown in 10% 
CO2. On the day prior to transfection 100,000 cells are seeded in 20mm (in 
diameter) glass Petri dishes in medium containing both FBS and 
penicillin/streptomycin. On the day of transfection the medium is changed 
to fresh media (still with FBS and penicillin/streptomycin). 0.5 µg pCFP-
MSH2 and 0.5 µg pYFP-MSH6 (WT or mutant) that was mixed with 3 µl 
Fugene6 transfection reagent (Roche, Basel, Switzerland) per dish. 
Transfections are performed according to the manufacturer’s protocol. Cells 
are then incubated for ~24 hours before visualization of transfection by 
confocal laser scanning microscopy (Zeiss LSM510, Carl Zeiss 





In silico analysis of the MSH6 UVs 
The results of the in silico analyses of the MSH6 UVs are presented in 
Table 2 and Figure 2. These data shows that four of the five UVs change 
highly conserved amino acids (p.Ser144Ile, p.Glu522Arg, p.Ala1021Asp, 
and p.Thr1219Ile), whereas 1 of the five UVs changes a reasonably good 
conserved amino acid (p.Ala326Val). 
Two of the five UVs (p.Ala326Val and p.Gln522Arg) are predicted to be 
benign based on PolyPhen, a program partially based on conservation. The 
other UVs were predicted to be possibly pathogenic based on the PolyPhen 
algorithm.   
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A study for the possible splicing effects of the UVs, as determined by 
Netgene2, SpliceSitefinder and Splice Site Predict, clarifies that one of the 
UVs (p.Ser144Ile) could have an alternative splicing due to an additional 
(occurring) acceptor site. Notably, this additional site has been predicted 
with the SpliceSiteFinder prediction program only and thus the 
consequences are not really clear.  
These in silico experiments suggest that the MSH6 UVs are likely to be 




Table 2. In silico analyses of the five tested MSH6 UVs.  
Polarity change on Amino acid substitutions: P=polar amino acid (AA), NP=non-polar AA, 
AP= acidic charged polar AA, BP= basic charged polar AA 
 
















P→ NP benign No change 
p.Gln522Arg 
(p.Q522R) 
P→ NP benign No change 
p.Ala1021Asp 
(p.A1021D) 













Figure 1. Schematic representation of the location of the five MSH6 missense mutations. 
            
 
 
Figure 2. Alignment of the human MSH6 protein with MSH6 proteins of different vertebrates 
and yeast. The alignment includes the (putative) MSH6 proteins of the following organism: 
Homo sapiens, Bos taurus, Canis familiaris, Gallus gallus, Mus musculus, Rattus 
norvegicus, Xenopus tropicalis, and Saccharomyces cerevisiae. Only protein regions that 
contain the tested UVs are presented in this figure. Identical amino acids (*), conserved 
substitutions (:), or semi-conserved substitutions (.) are marked. The multiple sequence 












Binding site for MG2+(AA1208-1228)
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Expression of wild type and mutant MSH6 in MSH2- and MSH6-deficient 
cells  
 
To evaluate whether the UVs affect protein stability, WT or mutant MSH6 
were transiently expressed in combination with MSH2 in LOVO cells. 
Representative results from 3 independent experiments are presented in 
Figure 3. Western blot analysis shows a strong reduction of MSH6 protein 
levels for the UV-containing proteins p.Ala1021Asp, p.Ala326Val, and 
p.Thr1219Ile when compared to MSH6 wildtype. The p.Ser144Ile mutant 
shows a slight decrease in MSH6 protein levels. The data suggest that 
these MSH6 mutant proteins are less stable, that the protein synthesis is 
lower or that the transcription of the gene is lower. The MSH6 p.Gln522Arg 
protein was expressed at levels that were comparable to wildtype MSH6 
protein levels (see Figure 3). 
 
 
Figure 3. Expression of MSH2 and MSH6 in LOVO cells.   
Cells were transiently transfected with pCDNA3.1-MSH2 and with pCDNA3.1-MSH6 (WT or 
containing one of the UVs). Controls on this blot are an MLH1-deficient cell line (HCT 116) 
















































Quantitative PCR analysis of MSH6 mRNA  
To differentiate between reduced transcription and reduced translation or 
protein stability, MSH6 mRNA levels were quantified in transiently 
transfected LOVO cells. Quantification of MSH6 mRNA levels showed 
significant differences between LOVO cells expressing wildtype MSH6 or 
the mutated gene (48 hours after transfection, see Figure 4). In particular 
the cell lines transfected with the four UV-containing plasmids showed 
lower levels of the MSH6 gene expression (p.Ala1021Asp, p.Ala326Val, 
p.Thr1219Ile, and p.Ser144Ile) indicating that for these four mutants the 



















Figure 4. Quantitative PCR-analysis 48 hours after transfection.  
Total RNA of transiently transfected LOVO cells expressing the MSH2 wildtype protein and 
wildtype MSH6 or one of five UVs were extracted 48 hours after transfection. MSH6 mRNA 
levels were quantified using real-time PCR. Y-axis represents the relative mRNA quantity of 
MSH6 normalized to the house keeping gene TBP. 
 
Localization experiments 
We investigated the co-localization of CFP-MSH2 and YFP-MSH6 (WT and 
five UV-containing proteins) in HeLa cells. Figure 5 shows representative 
results of these tansfections. All five MSH6 mutants localize to the nucleus 
when transfected together with wildtype MSH2 suggesting normal 
subcellular localization of all five MSH6 mutants. 
 
Yeast two-hybrid analyses for determining an interaction between MSH2 
and MSH6 
The yeast two-hybrid screen revealed that all five tested MSH6 UV-

















































































comparable with the interaction of wildtype MSH6 with wildtype MSH2 (see 
Figure 5). Unexpectedly, we observed colonies for the combination of the 
two empty vectors and the combination pAS2 with pACT2-MSH6. The 
observed colonies, however, were white whereas the colonies observed for 









Figure 5. Subcellular localization of CFP-MSH2 and YFP-MSH6 (WT and one of 5 UVs).  
Nuclear localization of MSH6 proteins can be seen.  
 
 Figure 6.  
Yeast two-hybrid assays for 
wildtype MSH6 and 5 UV-
containing MSH6 proteins in 
combination with the wildtype 
MSH2 protein. Panels 1-6 show 
the ß-gal assays for wildtype 
MSH2 (coupled to the GAL4 DNA 
binding domain) in combination 
with MSH6 (wildtype or one of 
the five UVs coupled to the DNA 
activation domain). Panels 7-11; 
negative controls. Panels 7 and 
8; MSH2(WT) coupled to the 
GAL4 DNA binding domain 
combined with the empty vector 
containing the GAL4 DNA 
activation domain or the GAL4 
DNA activation domain coupled 
to a truncated MSH6 protein.   
Panels 9-10; MSH6(WT) or truncated MSH6 (coupled to the GAL4 DNA activation domain) 
combined with the empty vector (containing the GAL4 DNA binding domain). Panel 11; the 




YFP-MSH6-Gln522Arg   YFP-MSH6-Ala1021Asp
WT-MSH6 p.Ser144Ile p.Gln522Arg p.Ala1021Asp








Yeast two hybrid assays showed that all five UV-containing MSH6 proteins 
were able to interact with WT-MSH2 and that these interactions are 
comparable to that between WT-MSH6 and WT-MSH2 showing that these 
mutations have no influence on the interaction between MSH6 and MSH2 
in yeast. Also localization studies showed that the five mutant proteins are 
present mostly in the nucleus as is the WT-MSH6. When however studying 
the protein expression and stability in vivo (in LOVO cells) we noticed a 
decreased expression for four of the five UVs (p.Ser144Ile, p.Ala1021Asp, 
p.Ala326Val and p.Thr1219Ile).  
Finding lower levels of the UV-containing proteins might be caused by; a) 
rapid degradation of the protein; b) lower levels of gene expression; c) a 
rapid degradation of the mRNA; d) mutations in the expression plasmid that 
lower the expression. 
 To determine whether the lower protein expression levels found were 
caused by lower gene expression we performed quantitative PCR on the 
transfected cells. These experiments showed that the RNA and protein 
levels show a positive correlation, low RNA levels relate to low protein 
levels. This makes it plausible that the observed low proteins levels for four 
of the five UVs are caused by low gene expression levels. What is causing 
the low expression levels? It might be that the UVs have an influence of the 
expression levels. Another option might be the presence of mutations in the 
vector, e.g. in the promoter region of MSH6. As however three MSH6 
mutated inserts were cloned out of pFastbac1-MSH6, the vector backbones 
of these three UVs are the same. As one of the three is showing normal 
expression (p.Gln522Arg) the differences in expression can not be 
explained by mutations in the vector. Likely, therefore, is an influence of the 
UVs on the expression level.  
In conclusion, it is not unlikely that four of the five tested MSH6 UVs are 
pathogenic. Some caution, however, might be considered. The tumours 
mostly show normal expression of MSH6 by immunohistochemical staining. 
These immunohistochemical stainings are not quantitative so difference 
between normal expression and low expression might be difficult to see. 
Moreover, when expressing the YFP-tagged MSH6 proteins in HeLa cells 
we did see normal expression. Additional experiments are thus needed to 
confirm pathogenicity. The prediction results are in line with the functional 
assays as described above, with the exception that the UV p.Gln522Arg is 
predicted to be benign. Furthermore, our analysis on splicing showed that 
the mutation c.431G>T could lead to an alternative splicing. 
 
Additional evidence  
Previously, the mutation p.Ser144Ile in the MSH6 protein was studied in a 
yeast-based functional assay (16) and in an in vitro MMR assay (17). In the 
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yeast-based assay, the mutation was thought to be pathogenic. As 
however the mutation occurs at a position that is not conserved in the yeast 
MSH6 protein (see figure 2) the data must be taken with great caution. In 
the in vitro assay (17), it was shown that the UV-containing MSH6 protein 
was as functional as wildtype MutSα. Combining our data with that of 
Kariola might indicate that, when our data is correct, the pathogenicity of 
the p.Ser144Ile is not directly linked to MMR function, but rather to lowered 
expression. 
Finding low expression is in agreement with previous observations that 
certain missense variants were associated with a markedly reduced 
expression of the corresponding allele in peripheral blood lymphocytes. 
Furthermore, it was suggested that transcript deregulation or unbalanced 
germline line expression of missense alleles may represent a relevant 
mechanism for MMR UVs (18).  
Finally, our data suggest that certain MSH6 UVs might be associated with 
down regulation of MSH6 mRNA levels in stead of a lower MMR 
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General discussion and future perspectives 
 
Carrier detection in Lynch syndrome 
Lynch syndrome, also known as hereditary non-polyposis colorectal cancer 
(HNPCC), is one of the most common hereditary cancer syndromes known 
worldwide. It is caused by germline mutations in one of the DNA mismatch 
repair (MMR) genes, MLH1, MSH2, MSH6 or PMS2 (1). Identifying a 
germline MMR mutation is important as inclusion of mutation carriers in 
cancer surveillance programs has proven to be life saving. Identification of 
mutation carriers, therefore, has been given major attention. As mutation 
analysis of all MMR genes in all patients with Lynch syndrome-associated 
tumours is not practical, several selection criteria for mutation screening of 
the MMR genes have been proposed. These selection criteria are based 
either on family history or on tumour tissue related assays such as 
microsatellite instability (MSI) or immunohistochemical staining of the MMR 
proteins (IHC) (2;3). When tumour tissue from affected patients suspected 
of having Lynch syndrome is unavailable, MMR gene mutation analysis can 
be offered to them, or in case DNA from the patients is unavailable as well, 
to their unaffected family members. However, this approach is time 
consuming and costly as all known Lynch syndrome genes, often in 
multiple family members, would need screening. In our experience, the 
situation of unavailable tumour tissues and DNA from affected relatives is 
not rare. Therefore, we decided to explore the possibility of a pre-screen 
method that would allow us to predict the presence of a germline mutated 
MMR gene in normal tissue of a possible carrier. The concept behind our 
approach was to detect a (50%) loss of expression (haploinsuffiency) due 
to this germline mutation. To detect this loss of expression we analyzed 
gene-expression by quantitative PCR of RNA and protein expression by 
Western blotting. The data we collected, however, made us conclude that 
the expression levels of MLH1 and MSH2, the two genes/proteins we 
analyzed, varied significantly, both within and between the groups of 
patients and controls. This variation in expression made it impossible to 
reliably predict the mutation carrier status (Chapter 2). As our proposed 
method did not work, alternatives should be considered. An option could be 
measuring allele-specific expression of the MMR genes in lymphocyte or 
lymphoblast cell lines. The allelic expression method differs from the 
method we applied as it measures the relative expression of both alleles 
separately. Variations in the expression levels of the MMR genes as 
detected by us are therefore not important. The group of Prof. Burn 
(Newcastle, UK) demonstrated on a poster at the InSIGHT meeting in 
Yokohama, Japan (2007) that this procedure indeed works. To do so, 
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however, one needs to be able to distinguish both alleles of a gene. If one 
wants to use this method for the three most commonly mutated genes 
(MSH2, MLH1 and MSH6) one first needs to identify informative coding 
polymorphisms in the three genes in the individuals that ask for screening. 
This clearly is a major drawback of the method.  
Another option might be to block the nonsense mediated RNA decay 
(NMD) pathway in cultured cells and compare the gene or protein 
expression levels before and after blocking (4;5). An increase of the gene 
expression or protein levels or an aberrant protein product after NMD 
inhibition, would indicate the presence of a mutation. A drawback of an 
NMD based method is that NMD is not able to breakdown messengers with 
mutations in the first and last exons of genes (6;7).  
One might also opt for a total different approach, namely solid phase 
sequencing (also called medical sequencing or deep sequencing). As this 
type of sequencing is getting cheaper and cheaper, sequencing all MMR 
genes in a single experiment is becoming affordable (8;9). These 
developments make it likely that our present concerns, that the screening of 
all genes in several individuals of a single family is too costly and too labour 
intensive, will be no longer valid before long.  
 
Missense mutations in Lynch syndrome 
After identifying a DNA variant one needs to decide whether the variant 
identified is involved in the development of the disease. For truncating 
mutations the decision is easily made. For missense variants and small in 
frame deletions or insertions this is far from easy (see chapter 3 review). It 
is therefore that these variants are called unclassified variants (UVs). A 
significant proportion of DNA variants found in Lynch syndrome (suspected) 
patients are such UVs: 32%, 18%, 38% and 87% for MLH1, MSH2,MSH6 
and MLH3, respectively (1). These UVs constitute a major problem in DNA 
diagnostics for Lynch syndrome.  
 
Database and decision making 
Screening the literature made clear that only a small proportion of the MMR 
UVs identified in Lynch syndrome suspected patients have been 
functionally tested. Until early 2007 we could find 115 UVs that were 
functionally characterized. The testresults for the UVs we came across in 
our literature search are collected in a database that is now online for all 
those interested (www.mmrmissense.info) (see also Chapters 3 and 4). An 
interesting finding when analyzing these data was that if the data from 
these studies indeed are correct, a large proportion of these UVs are 
probably pathogenic. For MLH1 70% (49/70) of the UVs were considered 
pathogenic by the authors. For MSH2 this was also 71% (25/35), while for 
MSH6 it was only 13% (1/8). However, we cannot exclude that these 
percentages are subject to ascertainment bias. 
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If indeed these data are true it would have a large impact on the carriers of 
these variants and their families and on how one should prescreen patients 
for mutation analysis. We should reconsider the inclusion criteria for 
mutation analysis, as some of them are based on finding truncating 
mutations only. For example, to date, a combination of a young age at 
diagnosis and /or a positive family history, with an MSI-H status and/or 
negative IHC for an MMR protein are generally considered as predictors 
and inclusion criteria for MMR mutation analysis (10;11)). Clearly, missense 
variant carriers would be excluded as in many cases the immuno-
histochemical staining would very likely be positive. Furthermore, some 
publications have shown that certain missense mutations (like E578G in 
MLH1) do not correlate with MSI (12). Validation of the data therefore is 
crucial. 
 
Functionally Testing UVs   
As mentioned, a large proportion of the UVs might be pathogenic, in 
particular when we consider MLH1 and MSH2. However, for MSH6 only 
eight UVs had been functionally tested and of these eight only one was 
considered pathogenic. As we have found a relative large number of UVs in 
MSH6 (13), we performed functional assays on 5 of these. These UVs were 
identified previously in patients suspected of Lynch syndrome. Although we 
did find differences in expression levels for some, we have no conclusive 
evidence that the 5 tested MSH6 UVs are involved in cancer development 
(chapter 6). Are these UVs, as most other MSH6 UVs, not involved in 
Lynch syndrome? Clearly, the assays used do not show dramatic effects 
for these UVs in the assays performed. Small effects, however, cannot be 
excluded. Furthermore, we only tested for specific functions of the proteins 
and did not yet determine mismatch repair functioning itself. We therefore 
can not exclude some involvement of these UVs in Lynch syndrome. Might 
these UVs be weak mutations (mutations with a small effect on the protein 
function), then the assays used might not detect the possible pathogenic 
nature of these mutations. Moreover, we know that the penetrance of 
MSH6 mutations can be lower than that of mutations in MSH2 and MLH1 
and we know that the age of onset is generally higher (14). It can therefore 
not be excluded that these UVs have a small but significant effect. Last but 
not least, we have identified the co-occurrence of a second MMR gene 
mutation several times, in particular in patients with MSH6 UVs (15;16). 
This might be coincidental but it might also point towards a more complex 
mode of inheritance. 
In addition to the UVs in MSH6 we also tested eight MLH3 UVs. As in the 
tested MSH6 UVs, we found no evidence that these variants contribute to 
disease development. Again, we can not totally exclude involvement of the 
UVs in disease development. For MLH3, involvement of the UVs as 
modifiers for the disease phenotype, rather than being high penetrant 
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mutations, seems even more likely as normal expression levels of this gene 
are very low when compared to MSH2 and MLH1 (17). 
 
Limitations of the functional assays 
All the assays performed and described in this thesis investigate specific 
aspects of MMR protein functioning. UVs that do not change the functional 
aspects analyzed may still lead to a MMR defect. Therefore, it should be 
emphasized that even if no obvious defects are found by such assays, 
pathogenicity can still not be totally excluded.  
On the other hand, when assays predict a pathogenic nature of a variant 
one should realize that it is of utmost importance that the proper positive 
and negative controls were included in the study. Besides these controls 
also the expression level of the transfected proteins should be kept in mind. 
High levels of these MMR proteins might be toxic or could disturb normal 
functioning of the overexpressed protein. Further, when only part of the 
protein is expressed (which is not the case in the assays performed by us 
and described in this thesis) this might also lead to findings that may not 
reflect the impact on function of a full-length protein.   
Possibly the biggest problem of functional assays is the fact that for hardly 
any of the assays the sensitivity and specificity has been determined. As 
long as a test has not been validated properly, results should be utilized 
with great caution.  
Taken together, the outcome of functional testing in its present state cannot 
always be used in clinical practice as direct proof of (non)pathogencity (see 
chapter 3 for a review)  
 
The future of functional assays 
Clearly, one of the greatest challenges in Lynch syndrome research is the 
development of more sensitive and well validated functional assays. One 
might opt, as we did, for different functional assays that each test a specific 
property of the protein. Another option might be a test that measures the 
DNA mismatch repair capacity as a whole. Because deficient mismatch 
repair is considered the source of accumulation of somatic mutations and 
thereby tumour development in Lynch syndrome, the most logical option 
would be to first test the repair capacity of the mutated protein. After 
demonstrating deficient mismatch repair, one might use specific tests to 
determine the precise effect the UV has on the mutated protein to support 
and understand the findings. In this approach, this first test would then be 
crucial. However, considering these repair assays, several things should be 
kept in mind. To name a few: the in vivo and in vitro differences that exist 
for proteins (in vivo expressed proteins e.g. undergo proper folding and 
many modifications); the amount of protein might be crucial (it should mimic 
the real situation) –for example, high levels of these proteins are toxic or 
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could disturb normal function of the proteins. And last but not least, using 
non-human test systems might give false positive or false negative results. 
 
At this moment a second major challenge is data interpretation. One surely 
needs to combine different arguments: determine MMR repair; perform in 
silico analysis of the variants (e.g. conservation of the amino acid, kind of 
amino acid change); use also indirect evidence such as segregation and 
MSI. And hopefully in the future, based on many tested UVs in validated 
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In this thesis we present a number of studies related to the classification of 
missense mutations in Lynch syndrome and we tested an alternative, 
tumourindependent approach for the identification of mismatch repair 
(MMR) mutation carriers. 
 
Identification of MMR mutation carriers. 
Identification of MMR-gene mutation carriers and enrolling mutation carriers 
in surveillance programs for the early detection of tumours has been shown 
to remarkably reduce the risk of colon cancer in the identified mutation 
carriers and of mortality due to colon cancer. Identification of mutation 
carriers, therefore, has been given considerable attention. However, as 
mutation analysis of all MMR genes is timeconsuming and costly, several 
clinical selection criteria and laboratory prescreening methods have been 
developed which help to decide whether or not a patient should be 
screened for mutations. The Dutch guidelines for the selection of patients 
for mutation analysis are based on the age at diagnosis, microsatellite 
instability screening, immunohistochemical screening of the MMR proteins 
in the tumour, methylation screening of the MLH1 promoter and BRAF 
mutation screening. When a tumour is microsatellite instable (MSI-H) 
and/or immunohistochemistry is negative for MSH6 and/or MSH2, mutation 
analysis will be performed. When MLH1 is negative by 
immunohistochemistry, tumours are first tested for a BRAF mutation and 
MLH1 promoter hypermethylation. Tumours with MLH1 promoter 
hypermethylation and a BRAF mutation will not be tested for germline 
mutations as this is evidence that points towards sporadic cases. Tumours 
without MLH1 promoter hypermethylation and without a BRAF mutation will 
be screened for a MMR mutation.  
When no tumour material (and or no DNA) from a patient or another 
affected family member is available one generally needs to screen all 
Lynch associated MMR genes for mutations often in multiple family 
members. We worked on an approach for which no tumour material is 
necessary and which is based on the expression levels of the MMR 
proteins/genes in leukocytes. What we were hoping to develop was a 
method that could detect the loss of the mutated MMR allele 
(haploinsuffiency) based on gene- or protein-expression levels. 
Haploinsuffiency would point directly to the mutated gene (in the germline) 
thereby saving time and money. We show (Chapter 2) that MMR gene 
expression in blood leukocytes is extremely low and that a direct analysis 
on blood leukocyte samples is therefore not possible. However, after a 
short-term culture of leukocytes the expression level of the MMR genes is 
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boosted making it possible to measure MMR protein or mRNA levels. 
Unfortunately, large deviations in expression levels, both at the RNA as 
well as at the protein level were detected in proven mutation carriers and 
healthy controls. We therefore had to conclude that this method could not 
be used for the accurate detection of MMR mutation carriers. 
 
Classification of missense mutations in Lynch syndrome 
Finding a DNA variant is one issue, deciding whether a DNA variant is 
pathogenic, in other words whether it is contributing to the disease 
phenotype is another. This decision is easily made for mutations that result 
in premature termination of translation and thus in loss of function. For 
mutations that do not lead to a truncated protein this decision is much more 
difficult. This type of DNA variants, consisting mostly of missense 
mutations, is usually called unclassified variant (UV). These UVs form a 
significant proportion of the DNA variants found in Lynch syndrome 
(suspected) patients. They consist of DNA variants that give rise to single 
amino acid substitutions or small in-frame deletions (~10% of both MSH2 
and MLH1 mutations). The question whether a UV contributes to the 
disease phenotype or merely represents a rare polymorphism, constitutes a 
major problem with obvious direct clinical consequences. In practice, it is 
difficult to determine pathogenecity. Most evidence is indirect such as 
segregation data, MSI, immunohistochemistry or absence of the UV in 
controls. We therefore believe that most proof for pathogenicity should 
come from functional assays. In chapter 3 all published functional assays 
applied to study MMR variants and the test outcome are reviewed. This 
information has been stored in an online database 
(www.mmrmissense.info) (see chapter 4). 
Although the database contains data on over a 100 functionally tested UVs, 
a much larger set of UVs has never been tested. One subset of mutations 
never tested are those identified in MLH3. Until now, 18 MLH3 germline 
mutations/UVs have been identified in colorectal cancer cases suspected of 
Lynch syndrome. Sixteen of these are UVs, all single amino acid 
substitutions, for which the pathogenic nature is yet unclear. In chapter 5, 
we functionally tested 8 MLH3 missense variants that we had previously 
identified in Lynch syndrome suspected patients. We determined protein 
expression and stability, protein localization and interaction of the mutant 
MLH3 proteins with MLH1. All 8 mutant MLH3 proteins were expressed at 
levels comparable to wild type MLH3. Furthermore, the mutant proteins all 
localized normally to the nucleus and they interacted normally with wild 
type MLH1. We therefore have found no proof that the 8 missense variants 
tested are involved in colon cancer development and thus in Lynch 
syndrome.  
Another subgroup of UVs that is underrepresented in the set of functionally 
tested UVs are those in MSH6. In chapter 6, functional assays have been 
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performed to evaluate the pathogenicity of 5 of such inherited MSH6 UVs 
found in patients suspected of Lynch syndrome. The mutated MSH6 
proteins, all containing single amino acid substitutions, were tested for 
expression and stability, interaction with MSH2, and for the subcellular 
localization. It was shown that protein expression of 4 of the 5 MSH6 
mutants (S144I, A1021D, A326V, and T1219I) was significantly decreased 
after transfection when compared with expression of the wild type MSH6. 
Quantitative PCR analyses of hMSH6 mRNA after transfection showed that 
possibly this could be due to lower mRNA levels. No effects were observed 
on MSH2-MSH6 protein-protein interaction and the subcellular localization 
was normal for all 5 MSH6 missense mutants. Our data show that 4 of the 
5 tested MSH6 UVs seem to have an influence on gene expression and 
thereby on protein translation. Why the expression of these 4 UVs in vivo is 
reduced is yet unknown. These UVs might therefore be pathogenic. Further 





































In dit proefschrift beschrijven we enkele studies die gericht zijn op het 
classificeren en karakteriseren van missense mutaties, DNA varianten die 
op eiwitniveau resulteren in aminozuurveranderingen, in zogenaamde 
MisMatch Repair (MMR) genen, respectievelijk eiwitten. De bestudeerde 
mutaties zijn eerder gevonden in patiënten met Lynch syndroom of in 
patiënten die daarvan werden verdacht. Verder hebben we een methode 
getest die het mogelijk zou moeten maken dragerschap van een MMR gen 
mutatie te identificeren (in tumor vrije individuen) zonder direct uitgebreid 
DNA mutatie onderzoek te hoeven doen. 
 
Identificatie van MMR-gen mutatie dragers 
Identificatie van MMR-gen mutatiedragers en het laten participeren van 
mutatiedragers in preventieve screeningsprogramma’s is bewezen 
succesvol te zijn, omdat het risico op het krijgen van dikkedarmkanker er 
door sterk afneemt en omdat het dikkedarmkanker gerelateerde 
sterfterisico sterk daalt. Vanwege deze waarnemingen krijgt het 
identificeren van mutatiedragers veel aandacht. We kunnen echter niet 
iedereen screenen op ziekteverwekkende mutaties in alle MMR-genen, dit 
is duur en kost relatief veel tijd. Daarom gaat de aandacht alleen uit naar 
mensen met een Lynch syndroom gerelateerde tumor en naar familieleden 
van dergelijke patiënten. Omdat in deze selecte groep mensen ook maar 
een klein deel een duidelijk ziekteveroorzakende MMR-gen mutatie heeft, 
zijn criteria (richtlijnen) opgesteld die moeten helpen bij het selecteren van 
patiënten en families die in aanmerking komen voor genetisch onderzoek. 
Deze criteria zijn gebaseerd op familiehistorie, leeftijd van de patiënt en op 
kenmerken van de tumor. De Nederlandse criteria met betrekking tot de 
tumorkarakteristieken zijn gebaseerd op: instabiliteit van microsatellieten 
(repeterende sequenties in het DNA), een kenmerk dat vrijwel altijd samen 
gaat met het verlies van functie van een MMR-gen; het verlies van een 
MMR-eiwit in de tumor (mogelijk als gevolg van een mutatie); methylatie 
van de promotor van één van de MMR-genen (MLH1); aanwezigheid van 
een mutatie in het B-RAF gen. Als een tumor microsatellietinstabiliteit laat 
zien (dit noemen we MSI-H) of als de tumor verlies laat zien van een MMR-
eiwit, en dan met name van MSH6 en/of MSH2, wordt mutatieonderzoek 
van het DNA van de patiënt ingezet. Als de MLH1 eiwitkleuring negatief is 
of als een tumor promotormethylatie van MLH1 laat zien en daarboven op 
ook een B-RAF mutatie heeft, dan wordt geen mutatie onderzoek verricht. 
Dit omdat het dan niet om een erfelijke tumor gaat. Patiënten met tumoren 
met een negatieve MLH1 kleuring zonder B-RAF mutatie worden wel 
verder onderzocht.  
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Als echter geen tumormateriaal aanwezig is, of als er geen DNA van een 
patiënt uit de familie kan worden onderzocht, dan rest slechts het screenen 
van alle MMR-genen, veelal in meerdere familieleden. Om dit te voorkomen 
hebben we aan een snelle, relatief goedkope methode gewerkt die het 
mogelijk zou moeten maken dragers van een MMR-genmutatie te 
identificeren aan de hand van de expressie van de MMR-genen in 
bloedcellen (leukocyten). De hypothese is dat dragers van een pathogene 
mutatie één van de twee kopieën van een gen heeft verloren en dat dit 
verlies leidt tot een halvering van de hoeveelheid RNA en eiwit. Het vinden 
van halvering van de expressie van een MMR-gen of van het MMR-eiwit 
zou richting geven aan de mutatiescreening. Dit zou tijd en geld besparen. 
In hoofdstuk 2 laten we zien dat de expressie van de MMR-genen extreem 
laag is in leukocyten. Door de leukocyten echter kort te kweken (3 dagen) 
gaat de expressie van de MMR-genen sterk omhoog waardoor deze goed 
meetbaar is. Als we de expressie bekijken, zien we helaas dat de niveaus 
van expressie erg variabel zijn. We vonden in controles soms zelfs een 
factor 2 verschil in expressieniveau. We moeten daarom concluderen dat 
deze methode niet bruikbaar is om dragers van MMR-genmutaties te 
identificeren. 
 
Classificatie van missense mutaties in Lynch syndroom 
Het vinden van een DNA-variant is één, het neme van een beslissing met 
betrekking tot de pathogeniciteit van de variant, met andere woorden, of de 
variant ook daadwerkelijk bijdraagt aan het ontstaan van de ziekte, is twee. 
De beslissing is eenvoudig te maken voor een mutatie die zorgt voor een 
verkort eiwit en dus voor een verlies van functie. Voor mutaties die niet 
leiden tot een verkort eiwit is het maken van een beslissing over 
betrokkenheid bij de ziekte een stuk lastiger. Dergelijke DNA-varianten, 
meestal DNA-veranderingen die leiden tot één aminozuurverandering of 
kleine in frame deleties of inserties, worden daarom ook wel unclassified 
variants, afgekort als UV’s, genoemd. 
UV’s worden vrijwel even vaak gevonden als de duidelijk 
ziekteverwekkende mutaties en dan vooral in patiënten die verdacht 
worden van Lynch syndroom (ongeveer 10% van deze patiënten heeft een 
dergelijke UV). Omdat het niet duidelijk is of de betreffende DNA-variant 
bijdraagt aan de ziekte kan de UV niet gebruikt worden in de kliniek. Wat 
kan er worden gedaan om dit wel mogelijk te maken? Indirect bewijs kan 
worden verkregen door te kijken naar microsatellietinstabiliteit in de tumor 
van de persoon in wie de UV is gevonden. Ook kan gekeken worden naar 
de frequentie waarin de UV in controlespersonen voorkomt en zou gekeken 
kunnen worden naar segregatie van de UV met het optreden van kanker in 
leden van de familie waarin de UV is gevonden. Direct bewijs wordt 
hiermee echter niet verkregen. Wij denken daarom dat functionele testen, 
die wel een direct bewijs geven, hieraan zouden moeten worden 
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toegevoegd. In hoofdstuk 3 worden alle functionele testen die ooit zijn 
beschreven voor het testen van UV’s in MMR-eiwitten uitgelegd en wordt 
een overzicht gepresenteerd van de gepubliceerde resultaten. De 
gegevens zijn online te bekijken op www.mmrmissense.info (Hoofdstuk 4). 
 
De database zoals beschreven in hoofdstuk 4 bevat 115 UV’s die zijn 
getest, echter dit is maar het topje van de ijsberg. De meeste gevonden 
UV’s zijn nog niet getest. Een set van UV’s die nog nooit zijn getest, zijn de 
UV’s gevonden in MLH3. Tot nu toe zijn 18 MLH3 UV’s beschreven in 
families verdacht van Lynch syndroom. In hoofdstuk 5 beschrijven we 
functionele testen voor 8 van de 18 gevonden MLH3 UV’s. We hebben 
gekeken naar: eiwitexpressie en eiwitstabiliteit, naar de subcellulaire 
lokalisatie van mutante eiwitten en de interactie van de mutante MLH3-
eiwitten met het wildtype MLH1-eiwit. Alle proeven laten zien dat de 
mutante eiwitten vergelijkbare resultaten laten zien als het wildtype MLH3. 
We concluderen daarom dat de 8 geteste MLH3 UV’s zeer waarschijnlijk 
geen belangrijke rol spelen in de ontwikkeling van tumoren bij de mensen 
waarin de UV’s zijn gevonden en dat de UV’s niet oorzakelijk zijn voor het 
Lynch syndroom. 
 
Een andere groep UV’s die nog maar beperkt zijn onderzocht, zijn de UV’s 
in MSH6. In hoofdstuk 6 hebben we functionele testen uitgevoerd op 5 
MSH6 UV’s die we eerder gevonden hadden in patiënten die verdacht 
werden van Lynch syndroom. De 5 missense varianten hebben we getest 
op expressie en stabiliteit van het mutante eiwit, op interactie met wildtype 
MSH2 en op de lokalisatie van het mutante eiwit in de cel. Alle eiwit-eiwit 
interactieproeven en de lokalisatieproeven lieten een normaal beeld zien 
(vergelijkbaar met wildtype MSH6). In de expressieproeven zagen we 
echter een verminderde expressie van 4 van de 5 MSH6 mutanten, te 
weten S144I, A326V, A1021D en T1219I, in vergelijking tot het wildtype 
MSH6 eiwit. Kwantitatieve PCR op MSH6 na transfectie liet zien dat de 
verminderde eiwitexpressie samengaat met een verminderde hoeveelheid 
MSH6 mRNA. Het lijkt er dus op dat de 4 UV’s invloed hebben op de 
hoeveelheid MSH6 mRNA en daarmee op de hoeveelheid MSH6 eiwit. De 
reden waarom de expressie verlaagd is, is nog onduidelijk. Vervolgstudies 
zijn nodig om hier meer inzicht in te verkrijgen. We kunnen daarom nog 
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